Document:

Exhibit 10.8

 

 

CONFIDENTIAL
TREATMENT REQUESTED UNDER RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

[*****] INDICATES
OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL
HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

 

EXECUTION
COPY

 

 

LICENSE
AGREEMENT

 

THIS LICENSE
AGREEMENT (the “Agreement”) is made effective as of the 28th day of April, 2010 (the “Effective Date”),
by and between AROG Pharmaceuticals LLC, a limited partnership organized and existing under the laws of the State of Texas, with
offices at Four Forest Plaza, 12222 Merit Drive, Suite 820, Dallas, Texas 75251 (“LICENSEE”), PFIZER Inc.,
a corporation organized and existing under the laws of Delaware with offices at 235 East 42nd Street, New York, New York 10017
(“PFIZER”) (each of PFIZER and LICENSEE, a “Party” and collectively, the “Parties”),
and solely for purposes of Sections 10.3.4, 10.3.5, 17.3 and 17.4, DAVA Oncology, LP, a limited partnership organized and existing
under the laws of the State of Texas, with offices at Four Forest Plaza, 12222 Merit Drive, Suite 280, Dallas, Texas 75251 (“DAVA”).

 

RECITALS

 

WHEREAS,
PFIZER Controls the Licensed IP (hereinafter defined) relating to CP-868596, a platelet-derived growth factor receptor-beta kinase
inhibitor; and

 

WHEREAS,
LICENSEE wishes to obtain, and PFIZER wishes to grant, certain licenses under the Licensed IP on the terms and conditions set
forth herein.

 

NOW, THEREFORE,
in consideration of the mutual agreements and covenants set forth herein and other good and valuable consideration, the receipt
and sufficiency of which the Parties hereby acknowledge, the Parties, intending to be legally bound hereby, agree to the foregoing
and as follows:

 

		1.	DEFINITIONS

 

		1.1	Defined Terms.
                                         Initially capitalized terms shall have the meaning ascribed to such terms in this Agreement,
                                         including the following terms which shall have the following respective meanings:

 

     

     

    
 

1.1.1       
“Active Candidate” means a Product that is the subject of (a) an IND filed with the FDA that has
gone into effect (as described in 21 C.F.R. 312.40) and that has not been withdrawn, terminated or inactivated or (b) an equivalent
thereof with respect to the European Union or Japan.

 

1.1.2       
“Affiliate” means, with respect to a Party, any Person that, directly or indirectly, through one
or more intermediaries, controls, is controlled by, or is under common control with that Party. For purposes of this definition,
“control” means: (a) the possession, directly or indirectly, of the power to direct the management or policies
of a Person, whether through ownership of voting securities, by contract or otherwise, or (b) the ownership, directly or indirectly,
of more than fifty percent (50%) of the total voting securities of, or other evidences of ownership interest in, such Person.

 

1.1.3       
“Applicable Laws” means all applicable laws, rules and regulations, including all rules, regulations,
guidelines or other requirements of any and all Regulatory Authorities that may be in effect from time to time.

 

1.1.4       
“Business Day” means any day other than a Saturday, a Sunday or a day on which commercial banks
located in New York, New York are authorized or required by law to remain closed.

 

1.1.5       
“Calendar Quarter” means each three (3) month period commencing on January 1, April 1, July 1 or
October 1 of each Calendar Year.

 

1.1.6       
“Calendar Year” means each twelve (12) month period commencing on January 1.

 

1.1.7       
“Commercialize” or “Commercialization” means to manufacture for sale, market,
promote, otherwise offer for sale, distribute and sell.

 

1.1.8       
“Commercially Reasonable Efforts” means: (a) with respect to Development of a Product, the efforts
and expenditures required (i) for such Product to remain an Active Candidate and (ii) to seek Regulatory Approval using such efforts
and expenditures comparable to those expended by LICENSEE (including through the use of Third Parties) to develop products that
are at a similar stage of development or product life cycle as the applicable Product and that are owned by LICENSEE or to which
LICENSEE otherwise has rights; and (b) with respect to Commercialization of a Product, using such efforts and expenditures comparable
to those expended by LICENSEE (including through the use of Third Parties) to Commercialize products that are at a similar stage
of development or product life cycle as the applicable Product and that are owned by LICENSEE or to which LICENSEE otherwise has
rights; provided that with respect to (a)(ii) and (b), the efforts and expenditures by LICENSEE shall be no less than the
greater of (x) the efforts and expenditures commonly expended by a Person similarly situated to LICENSEE with respect to products
that are at a similar stage of development or product life cycle as the applicable Product and that are owned by such Person or
to which such Person otherwise has rights and (y) where any rights and/or obligations hereunder have been sublicensed to a Third
Party, the efforts and expenditures commonly expended by such Third Party with respect to development and/or commercialization
(as applicable) of products that are at a similar stage of development or product life cycle as the applicable Product and that
are owned by such Third Party or to which such Third Party otherwise has rights.

 

    2 

     

    

 

1.1.9       
“Compound” means the compound known as CP-868596 that inhibits platelet-derived growth factor receptor-beta
kinase and its lactate salt (known as CP-868596-50) and benzenesulfonate salt (known as CP-868596-26), together with backup compound
CP-673451, each of the foregoing, as described on Schedule B, and all salts and formulations thereof.

 

1.1.10   
“Control” or “Controlled” means (a) with respect to any Intellectual Property,
the legal authority or right (whether by ownership, license or otherwise) of a Party to grant the applicable license, sublicense,
right or obligation to the other Party and (b) for materials and documents, a Party’s ability to provide the other Party
with, or provide the other Party with access to, such materials and/or documents, each of the foregoing (a) and (b) without violating
any contractual obligations or other arrangements with a Third Party or otherwise. For clarity, if a Party only can grant a license
or sublicense to Intellectual Property, or provide access to a material or document, of a limited scope due to an encumbrance
imposed by a Third Party, “Control” or “Controlled” shall be construed to so limit the license or sublicense
to such Intellectual Property or the provision of, or provision of access to, such materials or documents (as applicable).

 

1.1.11   
“Develop” or “Development” means to conduct research and development activities
(including related manufacturing activities) under conditions designed to yield data suitable for inclusion in an application
for Regulatory Approval of a Product by the FDA or a comparable agency in another country or regulatory jurisdiction within the
Territory.

 

1.1.12   
“Development Milestone” means the activities with respect to Development described on Schedule
A.

 

1.1.13   
“EU Major Market Country” means France, Germany, Italy, Spain or the United Kingdom.

 

1.1.14   
“FDA” means the United States Food and Drug Administration or any successor agency thereto.

 

1.1.15   
“Fees” means all fees that are payable by LICENSEE hereunder, including the Upfront Payment, the
Milestone Payments, Royalties, Sublicense Fees and any payments to Third Parties.

 

    3 

     

    

 

1.1.16   
“First Commercial Sale” means with respect to a Product, the first sale for use or consumption of
such Product in a country within the Territory. For clarity, the First Commercial Sale includes sales on a “named patient”
basis.

 

1.1.17   
“GAAP” means generally accepted accounting principles in the United States consistently applied.

 

1.1.18   
“IND” means: (a) an investigational new drug application filed with the FDA for authorization for
clinical investigation of any Product and (b) any foreign equivalents thereof as filed with any applicable Regulatory Authorities
in other countries or regulatory jurisdictions within the Territory.

 

1.1.19   
“Intellectual Property” means all copyrights, copyrightable subject matter, patents and patent applications,
Trademarks, moral rights, know-how and any and all other intellectual property or proprietary rights now known or hereafter recognized
in any jurisdiction.

 

1.1.20   
“Knowledge” means actual knowledge of the officers of PFIZER.

 

1.1.21   
“Know-How” means all confidential and proprietary information and data Controlled by PFIZER as of
the Effective Date, which: (a) were applied to, or incorporated into, any Product prior to the Effective Date and (b) are necessary
or useful for LICENSEE to Use any Product.

 

1.1.22   
“Licensed IP” means all Patent Rights and Know-How.

 

1.1.23   
“LICENSEE Inventory” means all components and works in process produced or held by LICENSEE with
respect to manufacture of Products.

 

1.1.24   
“Licensed Field” means all human and animal therapeutic, prophylactic and diagnostic Uses under
the Patent Rights, as described in the OSI License Agreement.

 

1.1.25   
“Market Exclusivity” means any data or market exclusivity periods, including any such periods listed
in the FDA’s Orange Book or periods under national implementations of Article 10.1(a)(iii) of Directive 2001/EC/83 and all
foreign equivalents thereof.

 

1.1.26   
“Milestone” means each milestone as set forth in the table in Section 5.1.2.

 

1.1.27   
“NDA” means: (a) a new drug application filed with the FDA and (b) any foreign equivalent thereof
as filed with any applicable Regulatory Authorities in other countries or regulatory jurisdictions within the Territory.

 

    4 

     

    

 

1.1.28   
“Net Sales” means the gross amount invoiced by, or on behalf of, LICENSEE, its Affiliates and their
respective sublicensees for sales of the Product, less the following deductions if and to the extent they are included in the
gross invoiced sales price of the Product or otherwise directly incurred by LICENSEE, its Affiliates and their respective sublicensees
with respect to the sale of the Product:

 

		(a)	rebates, quantity and cash discounts,
                                         and other usual and customary discounts to customers;

 

		(b)	taxes and duties paid, absorbed
                                         or allowed which are directly related to the sale of the Product;

 

		(c)	credits, allowances, discounts
                                         and rebates to, and chargebacks for spoiled, damaged, out-dated, rejected or returned
                                         Product;

 

		(d)	actual freight and insurance costs
                                         incurred in transporting the Product to customers;

 

		(e)	discounts or rebates or other payments
                                         required by any Applicable Laws, including any governmental special medical assistance
                                         programs; and

 

		(f)	customs duties, surcharges and
                                         other governmental charges incurred in connection with the exportation or importation
                                         of the Product (subsections (a) through (f), collectively, the “Deductions”).

 

Notwithstanding anything
to the contrary herein, sales between or among LICENSEE, its Affiliates and its and their sublicensees (the “Selling
Parties”) shall be excluded from Net Sales except where such Affiliates or sublicensees are end users, but Net Sales
shall include subsequent sales by the Selling Parties to Third Parties that are not Selling Parties.

 

The following principles
shall apply to calculating Net Sales:

 

		(x)	For the sale of any Product that
                                         is not invoiced, or is delivered before it is invoiced, Net Sales shall be calculated
                                         at the time of shipment or when such Product is paid for, if paid for before shipment
                                         or invoice.

 

		(y)	For the sale or other disposal
                                         of any Product for non-cash consideration, Net Sales shall be calculated as the fair
                                         market price of such Product in the country of sale or disposal. Notwithstanding the
                                         foregoing, provision of a Product to conduct pre-clinical or clinical research shall
                                         not be deemed to be a sale, so long as such Product is provided at a price that does
                                         not exceed the reasonably estimated cost of production and distribution thereof.

 

    5 

     

    

 

		(z)	Net Sales for a Combination Product
                                         (as defined herein) will be calculated on a country-by-country basis, as follows: (a)
                                         by multiplying actual Net Sales of such Combination Product in such country by the fraction
                                         A/(A+B) where A is the invoice price in such country of a Product containing the Compound
                                         as the sole active ingredient, if sold separately, and B is the total invoice price in
                                         such country of a product containing any other active ingredient in the Combination Product
                                         as the sole active ingredient, if sold separately; (b) if the other active ingredient(s)
                                         in the Combination Product are not sold separately in said country, by multiplying actual
                                         Net Sales of such Combination Product in such country by the fraction A/C where A is
                                         the invoice price in such country of a Product containing Compound as the sole active
                                         ingredient, if sold separately and C is the invoice price in such country of the Combination
                                         Product; (c) if neither a Product containing the Compound as the sole active ingredient
                                         nor any product(s) containing the other active ingredient(s) in the Combination Product
                                         as the sole active ingredient are sold separately in such country, in the manner calculated
                                         in the then currently largest market (by sales/country) for the Combination Product (other
                                         than the country at issue) where reference prices for the Combination Product, a product
                                         containing the Compound as the sole active ingredient and/or any product(s) containing
                                         any other active ingredient(s) at issue exist (but where no such prices have been established
                                         by, or under the direct influence of, any governmental entity or agency); and (d) where
                                         none of the foregoing clauses (a) through (c) apply, based upon the mutual agreement
                                         of the Parties as to the appropriate allocation between the Compound and any other active
                                         ingredient(s) in the Combination Product (which agreement shall not be unreasonably withheld
                                         or delayed by either Party).

 

		(aa)	Net Sales shall be determined
                                         from books and records maintained by LICENSEE in accordance with GAAP.

 

1.1.29   
“OSI” means OSI Pharmaceuticals Inc. (f/k/a Oncogene Science, Inc.).

 

1.1.30   
“OSI Agreements” means (1) *****; (2) *****; (3) *****; and (4) the OSI License Agreements; each
of the foregoing, as amended as of the Effective Date.

 

1.1.31   
“OSI License Agreements” means that (1) ***** and (2) *****, each of the foregoing, as amended as
of the Effective Date.

 

1.1.32   
“Paragraph IV Certification” means any certification filed pursuant to 21 U.S.C. §355(b)(2)(A)(iv)
or 355(j)(2)(A)(vii)(IV), or any notice under any future analogous provisions of Applicable Law in the United States (or any amendment
or successor statute thereto) or any comparable Applicable Law in any other country or regulatory jurisdiction in the Territory.

 

1.1.33   
“Patent Rights” means (a) the patents and patent applications listed in Schedule C; (b) all
divisionals, continuations, and continuations-in-part (to the extent the claims thereof are entirely supported by one or more
patents and patent applications listed on Schedule C to which it claims priority) that claim priority to the patents or
patent applications described in subsection (a); (c) any other subsequent patent application filings in any country worldwide
(to the extent the claims thereof are entirely supported by one or more patents and patent applications listed on Schedule
C to which it claims priority); and (d) all letters of patent granted with respect to any of the foregoing, and all patents
of addition, restorations, extensions, supplementary protection certificates, registration or confirmation patents, reissues and
re-examinations of any of the foregoing; each of the foregoing (a) through (d), to the extent Controlled by PFIZER.

 

    6 

     

    

 

1.1.34   
“Person” means an individual, corporation, partnership, limited liability company, trust, business
trust, association, joint stock company, joint venture, pool, syndicate, sole proprietorship, unincorporated organization, governmental
authority or any other form of entity not specifically listed herein.

 

1.1.35   
“Product” means any pharmaceutical product: (a) for which the manufacture, use, offer for sale,
sale, import or export would, if not for the license granted to LICENSEE hereunder, infringe a Valid Claim of the Patent Rights
in the country in which such product is used, offered for sale, sold, manufactured, imported or exported, or which otherwise incorporates,
utilizes, embodies or is Developed or manufactured using the Know-How and (b) that contains the Compound or an isomer, racemate,
solvate or derivative thereof to the extent described in the Patent Rights, either as the sole therapeutically active ingredient,
or in combination with other therapeutically active ingredients (the latter, a “Combination Product”); provided
that such product does not infringe, misappropriate or otherwise violate any Intellectual Property Controlled by PFIZER that
is not licensed to LICENSEE hereunder.

 

1.1.36   
“Regulatory Approval” means, with respect to a Product in any country or jurisdiction, any approval
(including where required, pricing and reimbursement approvals), registration, license or authorization that is required by the
applicable Regulatory Authority to market and sell such Product in such country or jurisdiction.

 

1.1.37   
“Regulatory Authority” means any governmental agency or authority responsible for granting Regulatory
Approvals with respect to a Product in the Territory.

 

1.1.38   
“Regulatory Filings” means, with respect to a Product, any submission to a Regulatory Authority
of any appropriate regulatory application, including any IND, NDA, any submission to a regulatory advisory board, any marketing
authorization application and any supplement or amendment thereto.

 

1.1.39   
“Residuals” means information in non-tangible form retained in the unaided memories of individuals
who have had access to the Products or Compounds, including ideas, concepts, know-how or techniques related thereto.

 

1.1.40   
“Royalty Term” means, on a country by country and Product by Product basis, the period beginning
on the Effective Date and expiring upon the later of: (a) expiration or abandonment of the last Valid Claim of the Patent Rights
in such country in the Territory with respect to such Product; (b) the expiration of any Market Exclusivity covering such Product
in such country; and (c) the tenth (10th) anniversary of the date of the First Commercial Sale of such Product in such country.

 

    7 

     

    

 

1.1.41   
“Tangible Materials” means all specimens, samples and inventory that PFIZER transfers to LICENSEE
pursuant to the term hereof.

 

1.1.42   
“Territory” means worldwide.

 

1.1.43   
“Third Party” means any Person other than a Party. For clarity, Affiliates shall be Third Parties.

 

1.1.44   
“Trademarks” means all registered and unregistered trademarks, service marks, trade dress, trade
names, logos, insignias, domain names, symbols, designs and combinations thereof.

 

1.1.45   
“United States” means the United States of America, its territories and possessions.

 

1.1.46   
“Use” means to make, have made, use, sell, offer for sale, import and export.

 

1.1.47   
“Valid Claim” means either: (a) a claim of an issued and unexpired patent included in the Patent
Rights, which has not been permanently revoked or declared unenforceable or invalid by an unreversed and unappealable or unreversed
and unappealed decision of a court or other appropriate body of competent jurisdiction; or (b) a claim of a pending patent application
included within the Patent Rights, which claim was filed in good faith and has not been revoked, cancelled, withdrawn, abandoned
or finally disallowed without the possibility of appeal or refiling of such application.

 

		1.2	Construction. For
                                         purposes of this Agreement: (a) words in the singular shall be held to include the plural
                                         and vice versa as the context requires; (b) the words “including” and “include”
                                         shall mean “including, without limitation,” unless otherwise specified; (c)
                                         the terms “hereof,” “herein,” “herewith,” and “hereunder,”
                                         and words of similar import shall, unless otherwise stated, be construed to refer to
                                         this Agreement as a whole and not to any particular provision of this Agreement; and
                                         (d) all references to “Section”, “Schedule” and “Exhibit,”
                                         unless otherwise specified, are intended to refer to a Section, Schedule or Exhibit of
                                         or to this Agreement.

 

		2.	LICENSE GRANT

 

		2.1	License Grant.

 

2.1.1       
Patent Rights. Subject to the terms and conditions of this Agreement, PFIZER hereby grants to LICENSEE an exclusive,
sublicensable (subject to Section 2.2), royalty-bearing right and license under the Patent Rights to Use the Products in the Licensed
Field within the Territory.

 

2.1.2       
Know-How. Subject to the terms and conditions of this Agreement, PFIZER hereby grants to LICENSEE an exclusive, sublicensable
(subject to Section 2.2), royalty-bearing right and license to the Know-How to Develop and Commercialize the Products in the Licensed
Field within the Territory.

 

    8 

     

    

 

		2.2	Sublicense Rights.
                                         LICENSEE may sublicense the rights granted to it pursuant to Sections 2.1.1 and 2.1.2
                                         to any Third Party upon prior written notice to PFIZER; provided that (a) PFIZER
                                         is afforded an opportunity to provide LICENSEE with comments regarding each proposed
                                         sublicensee and LICENSEE reasonably considers such comments and (b) each sublicense is
                                         made subject to, and consistent with, the terms and conditions of this Agreement and
                                         includes provisions that (i) require prior written notice to PFIZER in the event of an
                                         assignment of the sublicense to a Third Party, (ii) include PFIZER as a third party beneficiary,
                                         with rights to enforce the terms of such sublicense, (iii) require the sublicensee to
                                         indemnify, defend and hold harmless the Pfizer Indemnitees to the same extent and degree
                                         as LICENSEE has agreed to indemnify, defend and hold harmless the Pfizer Indemnitees
                                         pursuant to Section 11.1, (iv) require sublicensee, during the term of the applicable
                                         sublicensee agreement and until the later of three (3) years after termination or expiration
                                         of such agreement or the date that all statutes of limitation covering claims or suits
                                         that may be instituted for personal injury based on the sale or use of a Product have
                                         expired, to maintain the insurance coverage described in, and otherwise comply with,
                                         Sections 15.1 and 15.2 to the same extent and degree as LICENSEE has agreed to so maintain
                                         such insurance coverage and otherwise comply with Sections 15.1 and 15.2; and (v) grant
                                         PFIZER the right (in its sole discretion) to assume such sublicense if this Agreement
                                         terminates (provided that PFIZER shall not be obligated to fulfill any obligations
                                         to such sublicensees beyond those obligations required of PFIZER if this Agreement had
                                         not terminated) and if PFIZER does not exercise such right, such sublicense shall terminate.
                                         In no event shall LICENSEE’s granting of any sublicense relieve LICENSEE of any
                                         of its obligations under this Agreement. LICENSEE shall provide PFIZER with a true and
                                         complete copy of each sublicense and each amendment thereto within thirty (30) days after
                                         each such sublicense or amendment has been executed.

 

		2.3	Internal Research and
                                         Residuals. Notwithstanding anything to the contrary herein, PFIZER (a) retains all
                                         rights to the Licensed IP to Use the Products for internal research purposes and (b)
                                         may use the Residuals resulting from PFIZER’s access to, or work with, the Products
                                         for any purpose; provided that with respect to each of the foregoing (a) and (b),
                                         such rights shall not include rights to clinically Develop, Commercialize or Use (except
                                         for internal research purposes) any Products in the Licensed Field within the Territory.

 

		2.4	OSI Agreements. Notwithstanding
                                         anything to the contrary herein, all rights, licenses, sublicenses and obligations that
                                         are described herein and granted or imposed hereunder are subject to the terms of the
                                         OSI Agreements (including the license granted to OSI pursuant to *****).

 

		2.5	No Additional Rights.
                                         Nothing in this Agreement shall be construed to confer any rights upon LICENSEE by
                                         implication, estoppel or otherwise as to any technology or Intellectual Property Controlled
                                         by PFIZER or its Affiliates other than as expressly set forth herein with respect to
                                         the Licensed IP, regardless of whether such technology or Intellectual Property shall
                                         be dominant or subordinate to any Licensed IP.

 

    9 

     

    

 

		3.	TRANSFER ACTIVITIES

 

		3.1	Initial Transfer. PFIZER
                                         will use reasonable efforts to: (a) make available to LICENSEE currently available records
                                         set forth in Schedule D to the extent such exist and are Controlled by PFIZER
                                         as of the Effective Date and are necessary for LICENSEE to Develop the Products (collectively,
                                         “Documentation”) and (b) perform such other activities (including
                                         with respect to Regulatory Filings) to the extent pertaining to the Compound and with
                                         respect to Regulatory Filings, to the extent held by PFIZER, as set forth in Schedule
                                         D ((a) and (b), collectively, the “Transfer Activities”). PFIZER
                                         shall perform the Transfer Activities in accordance with Schedule D and shall
                                         provide written notice to LICENSEE upon completion of such efforts (the “PFIZER
                                         Transfer Notice”).

 

		3.2	Follow-up Period.
                                         For the six (6) month period following LICENSEE’s receipt of the PFIZER Transfer
                                         Notice (the “Transition Period”), if LICENSEE learns of any incomplete
                                         Transfer Activities, LICENSEE shall provide written notice to PFIZER and reasonably following
                                         receipt thereof, PFIZER shall use reasonable efforts to perform such Transfer Activities;
                                         provided that PFIZER’s obligation to perform the Transfer Activities pursuant
                                         to this Section 3.2 and Section 3.1 shall not exceed a total of ***** hours in the aggregate.

 

		4.	DEVELOPMENT AND COMMERCIALIZATION

 

		4.1	Development.

 

4.1.1       
Efforts. LICENSEE shall, and shall ensure that its Affiliates and sublicensees (as applicable), use Commercially Reasonable
Efforts to Develop the Products in the Territory, including conducting preclinical activities, clinical trial design and execution
and submission of Regulatory Filings in LICENSEE’s name to secure Regulatory Approval for the Products. LICENSEE’s
activities with respect to Developing the Products shall be at LICENSEE’s sole expense.

 

4.1.2       
Development Plan. LICENSEE shall Develop the Products in accordance with the development plan, attached hereto as Schedule
A, (the “Development Plan”) including by completing each Development Milestone within the time period specified
for each such Development Milestone in the Development Plan (each, a “Due Date”). LICENSEE’s failure
to achieve a Development Milestone by the applicable Due Date shall not be an automatic breach of this Agreement; provided
that (a) LICENSEE provides PFIZER with prompt written notice upon first learning that it will not achieve such Development
Milestone by the Due Date; (b) LICENSEE has exercised Commercially Reasonable Efforts with respect to achieving such Development
Milestone; and (c) LICENSEE achieves such Development Milestone by the alternative date that the Parties reasonably agree upon
as the due date for achieving such Development Milestone.

 

    10 

     

    

 

4.1.3       
Reports. During the Term, LICENSEE will provide PFIZER with a written report sixty (60) days after the last day of
each Calendar Year that includes a detailed written summary of all Development activities conducted by LICENSEE and its sublicensees
with respect to the Products, including LICENSEE’s compliance with its obligation to maintain the Product as an Active Candidate
pursuant to Section 4.1.1, progress with respect to the Development Milestones and expected timelines for future Development activities.

 

		4.2	Commercialization.

 

4.2.1       
Efforts. LICENSEE shall, and shall ensure that its Affiliates and sublicensees, use Commercially Reasonable Efforts
to Commercialize the Products in the Territory. LICENSEE will undertake such activities at its sole expense.

 

4.2.2       
Reports. During the Term, LICENSEE will provide PFIZER with a written report sixty (60) days after the first day of
January and July of each Calendar Year that includes a detailed written summary of all Commercialization activities conducted
by LICENSEE and its sublicensees with respect to the Products, including achievement of any Milestones.

 

		5.	PAYMENT TERMS

 

		5.1	Payment Terms.

 

5.1.1       
Upfront Payment. In partial consideration of the licenses and rights granted by PFIZER to LICENSEE hereunder, LICENSEE
shall pay to PFIZER a one-time, upfront, non-refundable and non-creditable payment of ***** upon ***** (“Upfront Payment”).
The Parties acknowledge and agree that the Upfront Payment is allocable as follows: *****.

 

5.1.2       
Milestone Payments. LICENSEE shall notify PFIZER as soon as practicable upon achievement of each Milestone set forth
below. In partial consideration of the licenses and rights granted to LICENSEE, within ***** of achieving each such Milestone,
LICENSEE shall pay to PFIZER the corresponding one-time, non-creditable and non-refundable milestone payment (each, a “Milestone
Payment”).

 

    11 

     

    

 

	MILESTONE	MILESTONE
    PAYMENT
	(1)
    The earlier of the date upon which: (a) the First Commercial Sale of a Product in the United States after receipt of Regulatory
    Approval in the United States occurs and (b) the combined aggregate Net Sales of Products in the United States equal *****	*****
	(2)
    The earlier of the date upon which: (a) the First Commercial Sale of a Product in an EU Major Market Country after receipt
    of Regulatory Approval in the European Union occurs and (b) the combined aggregate Net Sales of Products in the European Union
    equal *****	*****
	(3)
    The earlier of the date upon which: (a) the First Commercial Sale of a Product in Japan after receipt of Regulatory Approval
    in Japan occurs and (b) the combined aggregate Net Sales of Products in Japan equal *****	*****

 

For the avoidance of
doubt: (a) each Milestone Payment shall be payable only once upon achievement of the applicable Milestone, regardless of the number
of times such Milestone may be achieved (including with respect to different Products and indications) and (b) a Milestone satisfied
by a sublicensee or assignee of, or Third Party retained by, LICENSEE or its Affiliates shall be deemed to have been satisfied
by LICENSEE for purposes of this Section 5.1.2.

 

5.1.3       
Royalties.

 

		5.1.3.1	In partial consideration
                                         of the licenses and rights granted by PFIZER to LICENSEE hereunder, LICENSEE shall pay
                                         to PFIZER a royalty of ***** of Net Sales of Product in the Territory (collectively,
                                         “Royalties”); provided that the royalty rate applicable to
                                         Net Sales of a Product in the United States shall be ***** upon expiration or abandonment
                                         of the last Valid Claim of the Patent Rights filed in the United States that covers such
                                         Product. LICENSEE shall pay the Royalties to PFIZER for each Product on a country-by-country
                                         basis beginning on ***** and continuing for each such country until expiration of the
                                         Royalty Term for such Product in that country.

 

		5.1.3.2	Royalties based on
                                         Net Sales in a Calendar Quarter will be payable within ***** following the expiration
                                         of each such Calendar Quarter. All payments shall be accompanied by a report that includes
                                         reasonably detailed information regarding monthly calculation of all Net Sales of Product
                                         (including all gross invoiced sales and Deductions) and all Royalties payable to PFIZER
                                         for the applicable Calendar Quarter (including any foreign exchange rates employed).

 

    12 

     

    

 

5.1.4       
Sublicense Fees. In partial consideration of the licenses and rights granted to LICENSEE hereunder, LICENSEE shall
pay to PFIZER ***** of any and all consideration (except royalties directly attributable to Net Sales), whether such consideration
is in the form of up-front payments, royalties, milestone payments, or equity investments, paid by sublicensees in connection
with such sublicensee’s rights to the Licensed EP (“Sublicense Fees”). Sublicense Fees received during
a Calendar Quarter shall be paid to PFIZER within ***** following the expiration of such Calendar Quarter. All payments shall
be accompanied by a report that includes a calculation of all Sublicense Fees payable to PFIZER for the applicable Calendar Quarter.

 

5.1.5       
Payments under OSI Agreements. If Development, Commercialization or Use of a Product by LICENSEE or any of its sublicensees
triggers any payment obligations of PFIZER to OSI under the OSI License Agreements, PFIZER shall make such payments in accordance
with the terms of such agreements and LICENSEE shall have no obligation to pay such amounts to OSI; provided that LICENSEE
has paid PFIZER the amounts owed to PFIZER hereunder.

 

5.1.6       
Other Third Party Payments. Subject to PFIZER’s obligations in Section 5.1.5, LICENSEE shall be solely responsible
for all up-front payments, milestones, royalties and other payments that become due to any Third Party as a result of, or in connection
with, the Development, Commercialization or Use of the Products and/or LICENSEE’s exercise of its rights or performance
of its obligations hereunder.

 

5.1.7       
Other Payments. LICENSEE shall pay to PFIZER any other amounts due under this Agreement within ***** following receipt
of an invoice thereof from PFIZER.

 

5.1.8       
Late Payments. Any late payments shall bear interest, to the extent permitted by Applicable Laws, at *****. Such interest
shall be computed on the basis of a year of three hundred sixty (360) days for the actual number of days payment is delinquent.

 

		5.2	Payment Method.

 

5.2.1       
Any payments under Section 5 that are recorded in currencies other than the US dollar shall be converted into US dollars
at the average of the daily foreign exchange rates as reported by Bloomberg (or any other qualified source that the Parties mutually
agree upon in writing) for the Calendar Quarter in which such payments or expenses occurred, or for periods less than a Calendar
Quarter, the average of the daily rates as reported by Bloomberg for such period.

 

5.2.2       
All payments from LICENSEE to PFIZER shall be made by wire transfer in US dollars to the credit of such bank account
as may be designated by PFIZER in writing to LICENSEE. Any payment which falls due on a date which is not a Business Day may be
made on the next succeeding Business Day.

 

    13 

     

    

 

5.2.3       
If, by reason of Applicable Law in any country, it becomes impossible or illegal for LICENSEE, its Affiliates or sublicensees
to make royalty or other payments due hereunder to PFIZER in US dollars, or to make royalty or other payments due hereunder to
PFIZER, (a) if permitted by Applicable Law, such royalties or other payments due hereunder shall be deposited in local currency
in the relevant country to the credit of PFIZER in a recognized banking institution designated by PFIZER or, if none is designated
by PFIZER within thirty (30) days, in a recognized banking institution selected by LICENSEE, and identified in a notice in writing
given to PFIZER and (b) if not permitted under Applicable Law, the payment of such royalties or other payments shall be negotiated
promptly and in good faith by the Parties.

 

		5.3	Taxes.

 

5.3.1       
It is understood and agreed between the Parties that any amounts payable by LICENSEE to PFIZER hereunder are exclusive
of any and all applicable sales, use, VAT, GST, excise, property, and other taxes, levies, duties or fees (collectively, “Taxes”).
LICENSEE shall be responsible for billing and collection from its customers and remitting to the appropriate taxing authority
any and all Taxes which it is required to collect or remit. Each Party will be responsible for their own income and property taxes.

 

5.3.2       
If LICENSEE is required to make a payment to PFIZER subject to a deduction of tax or withholding tax (a “Withholding
Tax Requirement”), then the sum payable by LICENSEE (in respect of which such deduction or withholding is required to
be made) shall be decreased to the extent necessary to ensure that the amount required to be remitted is retained by LICENSEE
and LICENSEE shall remit the amount withheld in accordance with all Applicable Laws. Any such withholding taxes required under
Applicable Law to be paid or withheld shall be an expense of, and borne solely by, PFIZER.

 

5.3.3       
The Parties agree to cooperate and produce on a timely basis any tax forms or reports, including an IRS Form W-8BEN,
reasonably requested by the other Party in connection with any payment made by LICENSEE to PFIZER under this Agreement.

 

		6.	RELEVANT RECORDS; AUDIT RIGHTS

 

		6.1	Relevant Records. LICENSEE
                                         shall, and shall cause its Affiliates and sublicensees to, maintain accurate financial
                                         books and records pertaining to all Fees payable to PFIZER hereunder (including with
                                         respect to gross invoiced sales of the Products and calculation of all Deductions, Net
                                         Sales and Sublicense Fees) (collectively, “Relevant Records”). The
                                         Relevant Records shall be maintained for the longer of: (a) the period of time required
                                         by Applicable Law and (b) ***** following the date on which the amounts pertaining to
                                         the Relevant Records were paid.

 

    14 

     

    

 

		6.2	Audit Rights.

 

6.2.1       
Audit Request. During the period in which LICENSEE, its Affiliates and sublicensees are maintaining the Relevant Records,
PFIZER shall have the right to have an independent certified accountant reasonably acceptable to LICENSEE examine the Relevant
Records (regardless of whether such audit is on behalf of PFIZER or a Third Party to whom PFIZER has obligations to permit such
an audit, including OSI), but no more frequently than once every twelve (12) months, as may be necessary to verify compliance
with the terms of this Agreement. Such audit shall be requested in writing at least seven (7) days in advance and shall be conducted
during LICENSEE’s normal business hours at such place where the applicable records are customarily kept and in a manner
that minimizes any interference with LICENSEE’s business operations.

 

6.2.2       
Audit Fees and Expenses. PFIZER shall bear any and all fees and expenses it may incur in connection with any such audit
of the Relevant Records; provided that in the event an audit reveals an underpayment by LICENSEE of more than ***** as
to the period subject to the audit, LICENSEE shall reimburse PFIZER for any reasonable and documented out-of-pocket costs and
expenses of the audit within ***** after receiving invoices thereof.

 

6.2.3       
Payment of Deficiency. If any audit establishes that LICENSEE underpaid any amounts due to PFIZER under this Agreement,
then LICENSEE shall pay PFIZER any such deficiency within ***** after receiving written notice thereof and if the underpayment
by LICENSEE is more than ***** as to the period subject to the audit, such deficiency will be considered a late payment subject
to Section 5.1.8.

 

		7.	INTELLECTUAL PROPERTY

 

		7.1	Pre-existing IP. Subject
                                         to the rights and licenses expressly granted under this Agreement, each Party shall retain
                                         all right, title and interest in and to any and all Intellectual Property that are owned,
                                         licensed or sublicensed by such Party prior to, or independent of, this Agreement.

 

		7.2	Developed IP. LICENSEE
                                         shall own all right, title and interest in and to any Intellectual Property that are
                                         both: (a) related to the Compound and/or the Product, and (b) conceived solely by LICENSEE,
                                         its Affiliates, sublicensees and/or subcontractors following the Effective Date (collectively,
                                         “Developed IP”).

 

		7.3	Patent Prosecution.

 

7.3.1       
Patent Prosecution and Maintenance.

 

    15 

     

    

 

		7.3.1.1	LICENSEE shall be
                                         responsible for filing, prosecuting (including in connection with any reexaminations,
                                         oppositions and the like) and maintaining the Patent Rights in the Territory. LICENSEE
                                         shall file, prosecute and maintain the Patent Rights using qualified outside patent counsel
                                         and foreign patent associates selected by LICENSEE; provided that LICENSEE identifies
                                         such counsel for PFIZER in advance and PFIZER consents to such counsel (such consent
                                         not to be unreasonably withheld or delayed). LICENSEE shall be responsible for all costs
                                         and expenses in connection with such filing, prosecution and maintenance; provided
                                         that if LICENSEE provides PFIZER with a written request to abandon, or not file a
                                         patent application included in, any of the Patent Rights reasonably in advance of the
                                         relevant deadline: (a) LICENSEE shall no longer be responsible for such costs and expenses
                                         relating to filing, prosecuting and maintaining (as applicable) such Patent Right; (b)
                                         PFIZER may, or may allow a Third Party (including OSI) to, file, prosecute and maintain
                                         (in its sole discretion) such Patent Right; (c) upon PFIZER’s request, LICENSEE
                                         shall promptly provide all files related to filing, prosecuting and maintaining such
                                         Patent Right to counsel designated by PFIZER; and (d) the term “Patent Rights”
                                         automatically shall be modified to exclude such Patent Right as of the date LICENSEE
                                         provides such written request to PFIZER.

 

		7.3.1.2	Upon the written request
                                         of PFIZER or OSI, LICENSEE will provide PFIZER and/or OSI (as applicable) with (1) material
                                         correspondence with the relevant patent offices pertaining to LICENSEE’s prosecution
                                         of the Patent Rights and (2) a report detailing the status of all Patent Rights. LICENSEE
                                         will provide PFIZER a reasonable opportunity to review and comment on proposed material
                                         submissions to any patent office with respect to the Patent Rights prior to submission
                                         and LICENSEE shall reasonably consider any comments provided by PFIZER.

 

		7.3.1.3	The Parties hereby
                                         acknowledge that, as of the Effective Date, the Patent Rights are recorded in PFIZER’s
                                         name and PFIZER (in its sole discretion) may, or may have, such recordals updated to
                                         reflect PFIZER’s co-ownership with OSI.

 

7.3.2       
Assistance. LICENSEE (at its expense) shall be responsible for, and as reasonably requested by LICENSEE in writing,
PFIZER shall cooperate (at LICENSEE’s expense) with LICENSEE in, obtaining patent term restoration (including pursuant to
the Drug Price Competition and Patent Term Restoration Act), supplementary protection certificates or their equivalents and patent
term extensions with respect to the Patent Rights in the United States and Europe.

 

    16 

     

    

 

		8.	INFRINGEMENT; MISAPPROPRIATION

 

		8.1	Notification. Each
                                         Party will promptly notify the other Party in writing of (a) any actual or threatened
                                         infringement, misappropriation or other violation or challenge to the validity, scope
                                         or enforceability by a Third Party of any Licensed IP in the Licensed Field within the
                                         Territory of which it becomes aware (“Third Party Infringement”) and
                                         (b) any allegation by a Third Party that Intellectual Property owned by it is infringed,
                                         misappropriated or violated by the Development, Commercialization and/or Use of any Product
                                         of which it becomes aware (“Defense Action”).

 

		8.2	Third Party Infringement.

 

8.2.1       
LICENSEE shall have the first right (but not the obligation), at its own expense, to control enforcement of the Licensed
IP against any Third Party Infringement. Prior to commencing involvement in any such suit, action or proceeding, LICENSEE shall
consult with PFIZER and shall consider PFIZER’s recommendations regarding the proposed suit, action or proceeding, except
to the extent delay would result in the loss of rights by LICENSEE or PFIZER. LICENSEE shall give PFIZER timely notice of any
proposed settlement of any such suit, action or proceeding that LICENSEE controls and LICENSEE shall not settle, stipulate to
any facts or make any admission with respect to any Third Party Infringement without PFIZER’s prior written consent (not
to be unreasonably withheld) if such settlement, stipulation or admission would: (a) adversely affect the validity, enforceability
or scope, or admit noninfringement, of any of the Patent Rights; (b) give rise to liability of PFIZER, its Affiliates or OSI;
(c) grant to a Third Party a license or covenant not to sue under, or with respect to, any Intellectual Property Controlled by
PFIZER (including the Licensed IP); or (d) otherwise impair PFIZER’s, any of its Affiliates’ or OSI’s rights
in any Licensed IP or PFIZER’s or any of its Affiliates’ rights in this Agreement.

 

8.2.2       
PFIZER shall have the right (but not the obligation) to control, or permit OSI to control, enforcement of the Licensed
IP against any Third Party Infringement if LICENSEE provides PFIZER with written notice that it is not exercising its right to
control such enforcement or if such Third Party does not desist such Third Party Infringement or LICENSEE fails to initiate, or
file the relevant response to (as applicable), a suit, action or proceeding with respect to such Third Party Infringement upon
the earlier of: (a) expiration of the ninety (90) day period following PFIZER’s receipt of notice from LICENSEE of such
Third Party Infringement or (b) fifteen (15) prior to the deadline for filing, or filing the applicable response to (as applicable),
such suit, action or proceeding (including suits, actions or proceedings based on a Third Party’s filing of a Paragraph
IV Certification).

 

    17 

     

    

 

8.2.3       
Notwithstanding anything to the contrary herein, the Party that is not controlling the suit, action or proceeding pertaining
to enforcement of the Licensed IP against Third Party Infringement as described in this Section 8.2 may, at its sole discretion
and expense (subject to Section 8.3), join as a party to such suit, action or proceeding; provided that such Party shall
join as a party to such suit, action or proceeding upon the reasonable request and expense of the Party controlling such action
if necessary for standing purposes. The Party that is not controlling such a suit, action or proceeding shall have the right to
be represented by counsel (which shall act in an advisory capacity only, except for matters solely directed to such Party) of
its own choice and expense (subject to Section 8.3) in any such suit, action or proceeding.

 

8.2.4       
Any and all recoveries resulting from a suit, action or proceeding relating to a claim of Third Party Infringement
shall first be applied to reimburse each Party’s (and, as applicable, OSI’s) costs and expenses in connection with
such suit, action or proceeding, with any remaining recoveries retained by the Party that controlled such suit, action or proceeding
pursuant to this Section 8.2 (the “Remaining Recoveries”). Notwithstanding the foregoing, LICENSEE shall pay
PFIZER a Royalty in accordance with Section 5.1.3 on the Remaining Recoveries retained or received by LICENSEE as if such Remaining
Recoveries retained or received by LICENSEE were Net Sales in the Calendar Year in which the recoveries were retained or received.

 

		8.3	Defense Action. Upon
                                         LICENSEE’s request, PFIZER will reasonably cooperate with LICENSEE, at LICENSEE’s
                                         expense, to the extent necessary to defend LICENSEE or any sublicensee of LICENSEE in
                                         a Defense Action in which the claim of infringement, misappropriation or other violation
                                         is directed at LICENSEE’s or its sublicensee’s Use of the Compound (as such
                                         Compound exists as of the Effective Date) or the Know-How (in accordance with Section
                                         2). LICENSEE shall have all authority with respect to any Defense Action, including the
                                         right to exclusive control of the defense of any such suit, action or proceeding and
                                         the exclusive right to compromise, litigate, settle or otherwise dispose of any such
                                         suit, action, or proceeding; provided that LICENSEE shall keep PFIZER timely informed
                                         of the proceedings and filings, and provide PFIZER with copies of all communications,
                                         pertaining to each Defense Action and LICENSEE shall not settle, stipulate to any facts
                                         or make any admission with respect to any Defense Action without PFIZER’s prior
                                         written consent if such settlement, stipulation or admission would (a) adversely affect
                                         the validity, enforceability or scope, or admit noninfringement, of any of the Patent
                                         Rights; (b) give rise to liability of PFIZER, its Affiliates or OSI; (c) grant to a Third
                                         Party a license or covenant not to sue under, or with respect to, any Intellectual Property
                                         Controlled by PFIZER (including the Licensed IP); or (d) otherwise impair PFIZER’s,
                                         any of its Affiliates’ or OSI’s rights in any Licensed IP or PFIZER’s
                                         or any of its Affiliates’ rights in this Agreement.

 

		9.	CONFIDENTIALITY

 

		9.1	Definition. “Confidential
                                         Information” means the terms and provisions of this Agreement and other proprietary
                                         information and data of a financial, commercial or technical nature that a Party or any
                                         of its Affiliates (the “Disclosing Party”) has supplied or otherwise
                                         made available to the other Party or its Affiliates pertaining to the Compound, Product
                                         or such Disclosing Party’s obligations hereunder (the “Receiving Party”),
                                         whether disclosed in writing or otherwise. All Know-How shall be considered PFIZER’s
                                         Confidential Information.

 

    18 

     

    

 

		9.2	Obligations. The
                                         Receiving Party will protect all Confidential Information of the Disclosing Party against
                                         unauthorized disclosure to Third Parties with at least the same degree of care as the
                                         Receiving Party uses for its own similar information, but in no event less than a reasonable
                                         degree of care. The Receiving Party may disclose the Confidential Information of the
                                         Disclosing Party to its Affiliates, and their respective directors, officers, employees,
                                         subcontractors, sublicensees, consultants, attorneys, accountants, banks and investors
                                         (collectively, “Recipients”) who have a need-to-know such information
                                         for the Receiving Party to exercise its rights and perform its obligations hereunder;
                                         provided that such Recipients shall be subject to confidentiality obligations
                                         (whether by written contract or operation of law) at least as restrictive as those set
                                         forth herein. Notwithstanding anything to the contrary herein, PFIZER shall have the
                                         right to disclose Confidential Information of LICENSEE to OSI solely to the extent necessary
                                         to exercise its rights and comply with its obligations under the OSI Agreements.

 

		9.3	Exceptions.

 

9.3.1       
The obligations under this Section 9 shall not apply to any information to the extent the Receiving Party can demonstrate
by competent evidence that such information:

 

		(a)	is (at the time of disclosure)
                                         or becomes (after the time of disclosure) known to the public or part of the public domain
                                         through no breach of this Agreement by the Receiving Party or any Recipients to whom
                                         it disclosed such information;

 

		(b)	was known to, or was otherwise
                                         in the possession of, the Receiving Party prior to the time of disclosure by the Disclosing
                                         Party;

 

		(c)	is disclosed to the Receiving Party
                                         on a non-confidential basis by a Third Party who is entitled to disclose it without breaching
                                         any confidentiality obligation to the Disclosing Party; or

 

		(d)	is independently developed by,
                                         or on behalf of, the Receiving Party or any of its Affiliates without use or access to
                                         the Confidential Information as evidenced by written records.

 

9.3.2       
The restrictions set forth in this Section 9 shall not apply to any Confidential Information that the Receiving Party
is required to disclose pursuant to an order of a court or other governmental authority or as required by Applicable Laws (including
regulations promulgated by any applicable securities exchange); provided that the Receiving Party: (a) provides the Disclosing
Party with prompt notice of such disclosure requirement if legally permissible; (b) reasonably cooperates with the Disclosing
Party to oppose or limit, or secure confidential treatment for, such required disclosure; and (c) if the Disclosing Party is unsuccessful
in its efforts pursuant to subsection (b), discloses only that portion of the Confidential Information that it is advised by counsel
that it is legally required to disclose.

 

    19 

     

    

 

9.3.3       
Notwithstanding anything to the contrary herein, if PFIZER wishes to assign, pledge or otherwise transfer its rights
to receive some or all Milestone Payments and/or Royalties payable hereunder, PFIZER may disclose LICENSEE’s Confidential
Information to a Third Party in connection with any such proposed assignment; provided that PFIZER shall ensure that such
Third Parties are subject to confidentiality obligations (whether by written contract or operation of law) at least as restrictive
as those set forth herein.

 

		9.4	Right to Injunctive
                                         Relief. The Parties hereby agree that breaches of this Section 9 may cause irreparable
                                         harm and shall entitle the non-breaching Party, in addition to any other remedies available
                                         to it (subject to the terms of this Agreement), the right to seek injunctive relief enjoining
                                         such action.

 

		9.5	Ongoing Obligation
                                         for Confidentiality. Upon expiration or termination of this Agreement, the Receiving
                                         Party shall, and shall cause its Recipients to, destroy or return (as requested by the
                                         Disclosing Party) any Confidential Information of the Disclosing Party; provided that
                                         the Receiving Party (a) may retain one copy in its confidential files for the sole
                                         purpose of ascertaining its ongoing rights and responsibilities in connection with this
                                         Agreement and (b) shall not be required to destroy any computer files created during
                                         automatic system back-up that are stored securely.

 

		10.	REPRESENTATIONS, WARRANTIES AND COVENANTS

 

		10.1	Representations and
                                         Warranties by Each Party. Each Party represents and warrants to the other Party as
                                         of the Effective Date that: (a) it is duly organized, validly existing, and in good standing
                                         under the laws of its jurisdiction of formation; (b) it has full power and authority
                                         to execute, deliver and perform under this Agreement, and has taken all corporate action
                                         required by all Applicable Laws and its organizational documents to authorize the execution
                                         and delivery of this Agreement and the consummation of the transactions contemplated
                                         by this Agreement; (c) this Agreement constitutes a valid and binding agreement enforceable
                                         against it in accordance with its terms; and (d) this Agreement does not violate any
                                         other agreement to which it is bound.

 

		10.2	Representations and
                                         Warranties by PFIZER. As of the Effective Date:

 

10.2.1   
PFIZER represents and warrants that, to its Knowledge, there is no claim pending or threatened alleging that the Use
of the Licensed IP in the Licensed Field within the Territory infringes, misappropriates or otherwise violates the Intellectual
Property of a Third Party;

 

    20 

     

    

 

10.2.2   
PFIZER represents and warrants that, to its Knowledge, there is no claim pending or threatened by PFIZER alleging that
a Third Party is or was infringing, misappropriating or otherwise violating the Licensed IP in the Licensed Field within the Territory;

 

10.2.3   
PFIZER represents and warrants that the Licensed IP is Controlled by PFIZER such that it can grant the licenses to
the Patent Rights and Know-How to LICENSEE pursuant to Section 2, and further warrants and represents that the materials and documents
to be provided by PFIZER to LICENSEE hereunder (including the United States IND’s for the Compound) are Controlled by PFIZER
such that PFIZER has the ability to transfer such materials and documents to LICENSEE as provided herein;

 

10.2.4   
PFIZER represents and warrants that PFIZER is not a party to any agreement or other written arrangement with any Third
Party, other than OSI, pursuant to which such Third Party is granted a license to the Licensed IP with respect to the Products,
and further represents and warrants that PFIZER has not received any written notice from OSI regarding any outstanding disputes
in connection with which OSI is making a claim, demand or request for any reversionary rights in or to the Licensed IP; and

 

10.2.5   
PFIZER represents and warrants that no subjects are enrolled in clinical studies of the Compound that are sponsored
by PFIZER, all invoices from sites that participated in any such studies have been paid in full, and all invoices from any vendors
that supplied goods or services in connection with such studies have been paid in full.

 

		10.3	Covenants and Representations
                                         and Warranties by LICENSEE.

 

10.3.1   
LICENSEE represents and warrants that it has, and will continue to have during the Term hereof, the financial (including
cash to fund the obligations herein and complete each activity in the Development Plan by the applicable Due Date), developmental
and commercial capabilities (whether through agreements with Third Parties or otherwise) to Develop and Commercialize the Products
and comply with all other obligations in accordance with this Agreement.

 

10.3.2   
LICENSEE represents and warrants that it shall, and it shall ensure all Third Parties that it engages, comply with
all Applicable Laws in connection with performance of its obligations and exercise of its rights hereunder.

 

10.3.3   
As of the Effective Date, there shall be a total of ***** deposited in the bank account of LICENSEE.

 

    21 

     

    

 

10.3.4   
LICENSEE and DAVA represent and warrant that LICENSEE and DAVA, after giving effect to the transactions and payments
contemplated by this Agreement, are Solvent and that each are able to pay each of their debts as they become due. As used in this
Section, the term “Solvent” means, with respect to a particular date, that on such date, (a) the sum of the
assets, at a fair valuation, of LICENSEE and DAVA (on a consolidated basis) and of each of them (on a stand-alone basis) will
exceed their respective debts; (b) each of LICENSEE and DAVA (on a consolidated basis) and each of them (on a stand-alone basis)
has not incurred and does not intend to incur, and does not believe that it will incur, debts beyond its ability to pay such debts
as such debts mature; and (c) each of LICENSEE and DAVA (on a consolidated basis) and each them (on a stand-alone basis) has sufficient
capital with which to conduct its business. For purposes of this Section 10.3.4. only, “debt” means any liability
on a claim, and “claim” means any (i) right to payment whether or not such a right is reduced to judgment, liquidated,
unliquidated, fixed, contingent, matured, unmatured, disputed, undisputed, legal, equitable, secured or unsecured or (ii) any
right to an equitable remedy for breach of performance if such breach gives rise to a payment, whether or not such right to an
equitable remedy is reduced to judgment, fixed, contingent, matured, unmatured, disputed, undisputed, secured or unsecured.

 

10.3.5   
LICENSEE and DAVA represent and warrant that neither LICENSEE nor DAVA has any debts, claims, liabilities or obligations,
whether accrued or fixed, absolute or contingent (including any off-balance sheet financing), whether or not the same would be
required by GAAP to be stated in financial statements or disclosed in the notes thereto.

 

		10.4	No Other Warranties.

 

10.4.1   
EXCEPT AS EXPRESSLY STATED IN THIS ARTICLE 10, NEITHER PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTIES OF
ANY KIND, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO WARRANTIES OF TITLE, NON-INFRINGEMENT,
VALIDITY, ENFORCEABILITY, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. ANY INFORMATION, DOCUMENTS AND MATERIALS PROVIDED
BY PFIZER OR ITS AFFILIATES IS MADE AVAILABLE ON AN “AS IS” BASIS, WITHOUT WARRANTY WITH RESPECT TO COMPLETENESS,
COMPLIANCE WITH APPLICABLE LAWS, INCLUDING REGULATORY STANDARDS OR REGULATIONS, FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER
KIND OF WARRANTY, WHETHER EXPRESS OR IMPLIED.

 

10.4.2   
LICENSEE acknowledges and agrees that the Tangible Materials are experimental in nature and may have unknown characteristics.
LICENSEE shall use prudence and reasonable care in the use, handling, storage, transportation, disposition and containment of
the Tangible Materials. PFIZER makes no representations or warranties, and assumes no liability, with respect to the Tangible
Materials and LICENSEE’s or any Third Party’s use thereof.

 

    22 

     

    

 

		11.	INDEMNIFICATION

 

		11.1	Indemnification by
                                         LICENSEE. LICENSEE agrees to indemnify, hold harmless and defend PFIZER and its Affiliates,
                                         and their respective officers, directors, employees, contractors, agents, assigns and
                                         licensors (including OSI) (collectively, “Pfizer Indemnitees”), from
                                         and against any and all Third Party demands, claims, actions and proceedings (whether
                                         criminal or civil, in contract, tort or otherwise) for losses, damages, liabilities,
                                         costs and expenses (including reasonable attorneys’ fees) (each, a “Claim”)
                                         arising or resulting from: (a) the Development, Commercialization and/or Use of a Product
                                         by LICENSEE, DAVA or either of their Affiliates, subcontractors or sublicensees; (b)
                                         the negligence, recklessness or wrongful intentional acts or omissions of LICENSEE, DAVA
                                         or either of their Affiliates, subcontractors or sublicensees; (c) breach by LICENSEE
                                         or DAVA of any representation, warranty or covenant as set forth in this Agreement or
                                         (d) breach by LICENSEE or any of its sublicensees of the scope of the licenses set forth
                                         in Section 2, except, in each case, to the extent such Claims arise or result from (x)
                                         the negligence, recklessness or wrongful intentional acts or omissions of PFIZER or its
                                         Affiliates; and/or (y) breach by PFIZER of any representation, warranty or covenant as
                                         set forth in this Agreement.

 

		11.2	Indemnification by
                                         PFIZER. PFIZER agrees to indemnify, hold harmless and defend LICENSEE and its Affiliates,
                                         and their respective officers, directors, employees, contractors, agents and assigns
                                         (collectively, “Licensee Indemnitees”), from and against any and all
                                         Third Party Claims arising or resulting from: (a) the negligence, recklessness or wrongful
                                         intentional acts or omissions of PFIZER or its Affiliates; and/or (b) breach by PFIZER
                                         of any representation, warranty or covenant as set forth in this Agreement, except, in
                                         each case, to the extent such Claims arise or result from (x) the Development, Commercialization
                                         and/or Use of a Product by LICENSEE, DAVA or either of their Affiliates, subcontractors
                                         or sublicensees; (y) the negligence, recklessness or wrongful intentional acts or omissions
                                         of LICENSEE, DAVA or either of their Affiliates, subcontractors or sublicensees; (z)
                                         breach by LICENSEE or DAVA of any representation, warranty or covenant as set forth in
                                         this Agreement or (aa) breach by LICENSEE or any of its sublicensees of the scope of
                                         the licenses set forth in Section 2.

 

		11.3	Indemnification Procedure.
                                         In connection with any Claim for which a Party (the “Indemnified Party”)
                                         seeks indemnification pursuant to this Agreement, the Indemnified Party shall: (a) give
                                         the other Party (the “Indemnifying Party”) prompt written notice of
                                         the Claim; provided that failure to provide such notice shall not relieve the
                                         Indemnifying Party of its indemnification obligation hereunder, except and only to the
                                         extent that the Indemnifying Party actually is prejudiced as a direct result of such
                                         failure to provide notice; (b) cooperate with the Indemnifying Party, at the Indemnifying
                                         Party’s expense, in connection with the defense and settlement of the Claim; and
                                         (c) permit the Indemnifying Party to control the defense and settlement of the Claim;
                                         provided further that the Indemnifying Party may not settle the Claim without
                                         the Indemnified Party’s prior written consent, which shall not be unreasonably
                                         withheld or delayed, if such settlement materially adversely impacts the Indemnified
                                         Party’s rights or obligations. Further, the Indemnified Party shall have the right
                                         to participate (but not control) and be represented in any suit or action by counsel
                                         of its selection (which shall act in an advisory capacity only) and at its own expense.

 

    23 

     

    

 

		12.	LIMITATION OF LIABILITY

 

		12.1	Consequential Damages
                                         Waiver. EXCEPT FOR A BREACH OF SECTION 9 OR OBLIGATIONS ARISING UNDER SECTION 11
                                         OR AN ACT OF WILLFUL MISCONDUCT OR A BAD FAITH BREACH OF THE TERMS HEREOF, NEITHER PARTY
                                         SHALL BE LIABLE FOR ANY INDIRECT, CONSEQUENTIAL, SPECIAL, EXEMPLARY OR PUNITIVE DAMAGES,
                                         INCLUDING DAMAGES FOR LOST PROFITS OR LOST REVENUES REGARDLESS OF WHETHER IT HAS BEEN
                                         INFORMED OF THE POSSIBILITY OR LIKELIHOOD OF SUCH DAMAGES OR THE TYPE OF CLAIM, CONTRACT
                                         OR TORT (INCLUDING NEGLIGENCE).

 

		12.2	Liability Cap. EXCEPT
                                         FOR PFIZER’S BREACH OF SECTION 9, IN NO EVENT SHALL PFIZER’S LIABILITY FOR
                                         DAMAGES IN CONNECTION WITH THIS AGREEMENT EXCEED *****, REGARDLESS OF WHETHER PFIZER
                                         HAS BEEN INFORMED OF THE POSSIBILITY OR LIKELIHOOD OF SUCH DAMAGES OR THE TYPE OF CLAIM,
                                         CONTRACT OR TORT (INCLUDING NEGLIGENCE).

 

		13.	TERM; TERMINATION

 

		13.1	Term. The term
                                         of this Agreement shall commence as of the Effective Date and shall expire upon expiration
                                         of the last-to-expire Royalty Term (the “Term”). Upon expiration of
                                         the Royalty Term with respect to a Product and a country in the Territory, the licenses
                                         granted to LICENSEE under this Agreement shall convert to perpetual, non-exclusive, fully
                                         paid-up, royalty-free licenses with respect to such Product in such country.

 

		13.2	Termination For Failure
                                         to Pay. PFIZER shall have the right to terminate this Agreement in the event that
                                         LICENSEE fails to pay any Fee hereunder within ***** of the due date of the applicable
                                         Fee; provided that PFIZER provides LICENSEE with written notice of such failure
                                         to pay the applicable Fee.

 

		13.3	Termination for Cause
                                         Other Than Failure to Pay. Each Party shall have the right to terminate this Agreement
                                         if the other Party breaches any of its material obligations hereunder (except with respect
                                         to such breaches that are addressed in Section 13.2 or 13.5) and fails to cure such breach
                                         within ***** of receiving written notice thereof; provided that, if such breach
                                         is capable of being cured, but cannot be cured within such ***** period, and the breaching
                                         Party initiates actions to cure such breach within such period and thereafter diligently
                                         pursues such actions, the breaching Party shall have such additional period as is reasonable
                                         to cure such breach, but in no event will such additional period exceed *****. Any termination
                                         by a Party under this Section 13.3 shall be without prejudice to any damages or other
                                         legal or equitable remedies to which it may be entitled from the other Party. For the
                                         avoidance of doubt, LICENSEE’s failure to use Commercially Reasonable Efforts to
                                         Develop and Commercialize the Product shall constitute a material breach by LICENSEE
                                         under this Agreement.

 

    24 

     

    

 

		13.4	Termination for a
                                         Bankruptcy. Each Party shall have the right to terminate this Agreement in the event
                                         of any of the following: (a) the institution of any bankruptcy, receivership, insolvency,
                                         reorganization or other similar proceedings by or against the other Party under any bankruptcy,
                                         insolvency, or other similar law now or hereinafter in effect, including any section
                                         or chapter of the United States Bankruptcy Code, as amended or under any similar laws
                                         or statutes of the United States or any state thereof (the “Bankruptcy Code”),
                                         where in the case of involuntary proceedings such proceedings have not been dismissed
                                         or discharged within ***** after they are instituted; (b) the insolvency or making of
                                         an assignment for the benefit of creditors or the admittance by the other Party of any
                                         involuntary debts as they mature; (c) the institution of any reorganization, arrangement
                                         or other readjustment of debt plan of the other Party not involving the Bankruptcy Code;
                                         (d) appointment of a receiver for all or substantially all of the other Party’s
                                         assets; or (e) any corporate action taken by the board of directors of the other Party
                                         in furtherance of any of the foregoing actions.

 

		13.5	Termination for Challenge
                                         to Licensed IP. PFIZER shall have the right to immediately terminate this Agreement
                                         at any time after the Effective Date in its entirety or on a country-by-country basis
                                         in the event LICENSEE or any of its Affiliates or its or their sublicensees contests,
                                         challenges, supports or assists any Third Party to contest or challenge, in any patent
                                         office, court, regulatory agency or other forum, PFIZER’s ownership of, or rights
                                         in, or the validity, enforceability or scope of, any Licensed IP (and such shall be considered
                                         a material breach of this Agreement).

 

		13.6	Effect of Termination
                                         or Expiration.

 

13.6.1   
Upon termination or expiration of this Agreement, LICENSEE shall pay all Fees due as of the effective date of termination
or expiration within ***** following such effective date of termination or expiration.

 

13.6.2   
Upon termination of this Agreement, and subject to Section 13.6.4(d) below, LICENSEE shall have the right to sell its
remaining inventory of each Product following the termination of this Agreement; provided that (a) LICENSEE has fully paid,
and continues to fully pay when due, any and all Fees pursuant to the terms hereof; (b) LICENSEE is not in material breach of
this Agreement; and (c) ***** occurred prior to the effective date of termination.

 

    25 

     

    

 

13.6.3    
For the avoidance of doubt, upon termination of this Agreement, all licenses granted by PFIZER to LICENSEE and, at
PFIZER’s option, all sublicenses granted by LICENSEE in connection with this Agreement shall terminate.

 

13.6.4   
Upon termination of this Agreement by PFIZER:

 

		(a)	LICENSEE shall grant, and hereby
                                         grants, to PFIZER an exclusive, fully paid-up, royalty-free, worldwide, transferable,
                                         perpetual and irrevocable license, with the right to sublicense, to the Developed IP
                                         to the extent necessary or useful to (i) Develop, Commercialize or Use the Products or
                                         (ii) copy, distribute, make derivative works and otherwise exploit the Developed IP in
                                         connection with Developing, Commercializing and Using the Products, solely for such purposes.
                                         For clarity, LICENSEE retains all rights to the Developed IP in connection with products
                                         other than the Products.

 

		(b)	LICENSEE shall, at PFIZER’s
                                         request, undertake promptly and completely to (i) return to PFIZER or, at PFIZER’s
                                         option, to any of its Affiliates or a Third Party designated in writing by PFIZER (“Designated
                                         Affiliate/Third Party”) all Documentation, Items, Regulatory Filings and other
                                         regulatory-related documentation and materials provided by PFIZER to LICENSEE in connection
                                         with the Transfer Activities described in Schedule D and subsection (ii) of this
                                         Section, and (ii) perform the activities described in Schedule D (including the
                                         transfer of all Regulatory Filings, materials and documents) that PFIZER performed for
                                         LICENSEE for PFIZER or, at PFIZER’s option, the Designated Affiliate/Third Party;
                                         provided that LICENSEE shall perform such transfer and activities at LICENSEE’S
                                         expense and with respect to the Products and the Compounds as such exist as of the effective
                                         date of termination. LICENSEE shall transfer all materials, documents and Regulatory
                                         Filings pursuant to the foregoing in their current state as of the effective date of
                                         termination, reflecting Development and Commercialization efforts (including Regulatory
                                         Approvals and Trial Master Files, regardless of whether the clinical studies are completed)
                                         made by LICENSEE to the Compound and/or Product as of such date.

 

		(c)	To the extent that transfer of
                                         all Regulatory Filings and Regulatory Approvals held by LICENSEE with respect to the
                                         Products is not permitted by the applicable Regulatory Authority, LICENSEE shall permit
                                         PFIZER and, at PFIZER’s option, its Designated Affiliate/Third Party, to (and shall
                                         not itself, or permit any Third Parties to) cross-reference and rely upon any Regulatory
                                         Approvals and Regulatory Filings filed by LICENSEE with respect to the Products.

 

		(d)	LICENSEE shall, if requested by
                                         PFIZER, grant, and hereby grants, to PFIZER a fully paid-up, royalty-free, worldwide,
                                         transferable, sublicensable, perpetual and irrevocable exclusive license to use the Trademarks
                                         identifying Product(s) for the purpose of manufacturing, marketing, distributing and
                                         selling the Products.

 

    26 

     

    

 

		(e)	Upon PFIZER’s request, LICENSEE
                                         shall continue all ongoing activities that are reasonably necessary to continue Development
                                         and Commercialization of the Products for a mutually agreed upon migration period after
                                         termination of this Agreement, which period shall not be less than ***** unless otherwise
                                         agreed to in writing by the Parties (“Migration Period”), and PFIZER
                                         shall reimburse LICENSEE for LICENSEE’s reasonable out-of-pocket costs that are
                                         directly attributable to such activities and LICENSEE shall provide PFIZER with all gross
                                         proceeds that arc received (if any) in connection with the Products (including any and
                                         all sales thereof). During the Migration Period, LICENSEE shall provide such knowledge
                                         transfer and other training to PFIZER or, at PFIZER’s option, its Designated Affiliate/Third
                                         Party, as reasonably necessary for PFIZER or the Designated Affiliate/Third Party to
                                         continue research and development and Commercialization activities for the Product. In
                                         connection with such transfer and notwithstanding anything to the contrary herein, LICENSEE
                                         shall, at PFIZER’s option: (i) transfer to PFIZER or the Designated Affiliate/Third
                                         Party all Product *****; (ii) transfer to PFIZER or the Designated Affiliate/Third Party
                                         all LICENSEE Inventory owned by LICENSEE at *****; and (iii) assign to PFIZER or the
                                         Designated Affiliate/Third Party any agreements with Third Parties with respect to the
                                         Development or Commercialization of the Products. During the Migration Period, LICENSEE
                                         also shall transfer, or have transferred, all files related to filing, prosecuting and
                                         maintaining the Patent Rights to patent counsel or foreign associates designated by PFIZER,
                                         and provide such other assistance to PFIZER or, at PFIZER’s option, the Designated
                                         Affiliate/Third Party, to permit PFIZER or such Designated Affiliate/Third Party (as
                                         applicable) to control, or delegate control of, the filing, prosecuting and maintaining
                                         of the Patent Rights. LICENSEE shall be obligated to continue filing, prosecuting and
                                         maintaining all Patent Rights until the foregoing transfer of files related to filing,
                                         prosecuting and maintaining the Patent Rights is complete.

 

13.6.5   
Survival. Expiration or termination of this Agreement shall not relieve the Parties of any obligation accruing hereunder
prior to such expiration or termination. Without limiting the foregoing, the provisions of Sections 1, 2.3, 2.4, 2.5, 6, 7.1,
7.2, 9, 10.4, 11, 12, the second sentence of 13.1, 13.6, 14, 15, 16, 17.1, 17.2, 17.4, 17.5, 17.7 through 17.15, and any other
provisions that expressly specify that they survive shall survive expiration or termination of this Agreement; provided that
(a) Section 17.4 shall survive no later than ***** following the Effective Date and (b) the second sentence of Section 13.1
only shall survive with respect to Products for which, and in the countries in the Territory where, the Royalty Term has expired
as of the effective date of termination or expiration of the Agreement.

 

    27 

     

    

 

		14.	PUBLICITY

 

		14.1	Publicity.

 

14.1.1   
Subject to PFIZER’s rights pursuant to Section 13.6.4, neither Party (nor any of its Affiliates or agents) shall
use the Trademarks of the other Party or its Affiliates in any press release, publication or other form of promotional disclosure
without the prior written consent of the other Party in each instance.

 

14.1.2   
Each Party agrees not to issue any press release or other public statement, whether written, electronic, oral or otherwise,
disclosing the existence of this Agreement, the terms hereof or any information relating to this Agreement without the prior written
consent of the other Party, provided however, that neither Party will be prevented from complying with any duty of disclosure
it may have pursuant to Applicable Laws (including the rules of any recognized stock exchange) so long as the Disclosing Party
provides the other Party at least ten (10) Business Days prior written notice to the extent practicable and only discloses information
to the extent required by Applicable Law (including the rules of any recognized stock exchange).

 

		15.	LICENSEE INSURANCE

 

		15.1	Insurance Requirements.
                                         LICENSEE will maintain during the Term and until the later of: (a) three (3) years
                                         after termination or expiration of this Agreement or (b) the date that all statutes of
                                         limitation covering claims or suits that may be instituted for personal injury based
                                         on the sale or use of a Product have expired, commercial general liability insurance
                                         from a minimum “A-” AM Bests rated insurance company, including contractual
                                         liability, personal injury and product liability or clinical trials, with coverage limits
                                         of not less than ***** per claim and ***** in the aggregate. LICENSEE has the right to
                                         provide the total limits required by any combination of primary and umbrella/excess coverage.
                                         The minimum level of insurance set forth herein shall not be construed to create a limit
                                         on LICENSEE’s liability hereunder. Such policies shall name PFIZER and its Affiliates
                                         as additional insured (via CG20101185) and provide a waiver of subrogation in favor of
                                         PFIZER and its Affiliates. Such insurance policies shall be primary and non-contributing
                                         with respect to any other similar insurance policies available to PFIZER or its Affiliates.
                                         Any deductibles for such insurance shall be assumed by LICENSEE.

 

		15.2	Policy Notification.
                                         LICENSEE shall provide PFIZER with certified copies of such policies or original
                                         certificates of insurance evidencing such insurance: (a) prior to execution by both Parties
                                         of this Agreement and (b) prior to expiration of any one coverage. Such certificates
                                         shall provide that PFIZER shall be given at least thirty (30) days (ten (10) days in
                                         the case of cancellation for non-payment of premiums) written notice prior to cancellation,
                                         termination or any change to restrict the coverage or reduce the limits afforded.

 

    28 

     

    

 

		16.	DISPUTE RESOLUTION

 

		16.1	General. The following
                                         procedures shall be used to resolve any dispute, controversy or claim arising out of,
                                         or in connection with, this Agreement or the breach, termination or validity thereof
                                         (“Dispute”).

 

		16.2	Meeting. Promptly
                                         after receipt by a Party of the written request of the other Party, each of the Parties
                                         shall appoint a designated representative to meet in person or by telephone to attempt
                                         to resolve any Dispute. If the designated representatives do not resolve the dispute
                                         within fifteen (15) Business Days of such request, then an executive officer of each
                                         Party shall meet in person or by telephone to review and attempt to resolve the Dispute.
                                         The executive officers shall have fifteen (15) Business Days to attempt to resolve the
                                         dispute (“Executive Meeting Period”).

 

		16.3	Mediation. Subject
                                         to Section 16.5 herein, if, for any reason, the executive officers are unable to resolve
                                         the dispute within the Executive Meeting Period, either Party may, within fifteen (15)
                                         Business Days of expiration of the Executive Meeting Period, submit the dispute for resolution
                                         by mediation pursuant to the CPR (International Institute for Conflict Prevention and
                                         Resolution) Mediation Procedure as then in effect. The mediation shall be conducted in
                                         New York County, New York. At the request of both Parties, the mediator will provide
                                         an evaluation of the dispute and the Parties’ relative positions. Each Party shall
                                         bear its own costs and expenses with respect to the mediation. The Parties shall have
                                         thirty (30) Business Days from appointment of the mediator or sixty (60) Business Days
                                         from submission of the Dispute to mediation (whichever occurs sooner) to attempt to resolve
                                         the dispute through mediation.

 

		16.4	Arbitration. Any
                                         Dispute falling within Section 16.5 or which is not timely resolved pursuant to Sections
                                         16.2 and 16.3, or which has not been timely submitted to mediation in accordance with
                                         Section 16.3, shall, on either Party’s demand, be finally and exclusively resolved
                                         by binding arbitration in the manner described in this Section. The arbitration shall
                                         be held in accordance with the Commercial Arbitration Rules of the American Arbitration
                                         Association (“AAA”) then in effect (“the Rules”).
                                         If a Party intends to begin arbitration to resolve a Dispute, such Party shall provide
                                         written notice simultaneously to the other Party and the AAA in accordance with the Rules.
                                         Each Party shall designate one arbitrator within twenty (20) days of receipt by the respondent
                                         of the demand for arbitration, who shall be neutral and impartial and not an employee,
                                         director, or shareholder of the Party or of any Affiliate or sublicensee of the Party.
                                         The Party-appointed arbitrators shall select a third arbitrator within twenty (20) days
                                         of appointment of the second arbitrator, who shall be an attorney and an experienced
                                         arbitrator of large complex commercial cases, to serve as the chair of the arbitral tribunal.
                                         The third arbitrator shall not be an employee, director or shareholder of either Party
                                         or of an Affiliate or sublicensee of either Party. Arbitrators not timely appointed shall
                                         be appointed by the AAA in accordance with the listing, ranking and striking provisions
                                         of the Rules. The following general provisions shall apply to the arbitration proceeding:
                                         No later than thirty (30) days after the appointment of the third arbitrator, the arbitrators
                                         shall set a date for a hearing to resolve each issue in dispute identified by the Parties.
                                         The hearing shall take place no later than two hundred seventy (270) days from the receipt
                                         by the respondent of the demand to arbitrate, or as soon thereafter as practicable. Prior
                                         to the hearing, each Party shall produce, at the request of the other Party and subject
                                         to a confidentiality agreement, documents directly relating to the issue(s) in dispute,
                                         and permit the taking of not more than two (2) depositions by each Party. Each Party
                                         may submit a written brief or memorandum in support of its position which may be no more
                                         than fifty (50) pages. Unless the Parties agree otherwise or the arbitrators permit additional
                                         time for good cause shown, each Party shall be entitled to no more than eight (8) hours
                                         time to present testimony at the hearing. Each Party shall have the right to be represented
                                         by counsel. The arbitrators shall have sole discretion with regard to the admissibility
                                         of evidence. Admissibility will be decided by two-thirds vote. The award, which shall
                                         be a reasoned award briefly stating the findings of fact and conclusions of law on which
                                         it is based, shall be issued within thirty (30) days of the close of the hearing or as
                                         soon thereafter as practicable. Arbitration shall take place in New York, New York. All
                                         hearing costs shall be shared equally between the Parties. The arbitrators’ fees
                                         and expenses shall be shared equally by the Parties. The decision of the arbitrators
                                         shall be final and binding on the Parties and shall be enforceable in any court of competent
                                         jurisdiction.

 

    29 

     

    

 

		16.5	Certain Disputes.
                                         Notwithstanding anything to the contrary herein, with respect to Disputes pertaining
                                         to termination of this Agreement pursuant to Section 13, either Party may submit such
                                         Dispute for binding resolution by arbitration in accordance with Section 16.4 after expiration
                                         of the Executive Meeting Period without first submitting such Dispute for resolution
                                         in accordance with Section 16.3

 

		16.6	Provisional Relief/Submission
                                         to Jurisdiction. By agreeing to arbitration, the Parties do not intend to deprive
                                         any court of its jurisdiction to issue a pre-arbitral injunction, pre-arbitral attachment
                                         or other order in aid of arbitration proceedings and the enforcement of any award or
                                         to issue an order to maintain the status quo or prevent irreparable harm prior to the
                                         appointment of the arbitrators. Without prejudice to such provisional remedies as may
                                         be available under the jurisdiction of a court, the arbitrators shall have full authority
                                         to grant provisional remedies or order the Parties to request that a court modify or
                                         vacate any temporary or preliminary relief issued by such court, and to award damages
                                         for the failure of any Party to respect the arbitrators’ orders to that effect.
                                         The Parties hereby submit to the exclusive jurisdiction of the federal and state courts
                                         located in New York, New York (the “New York Courts”) for such purpose,
                                         and to the non-exclusive jurisdiction of the New York Courts for the enforcement of any
                                         arbitration award rendered hereunder.

 

    30 

     

    

 

		17.	GENERAL PROVISIONS

 

		17.1	Assignment. LICENSEE
                                         may not assign or otherwise transfer its rights or obligations under this Agreement or
                                         the license granted hereunder in whole or in part without the express prior written consent
                                         of PFIZER, which consent shall not be unreasonably withheld; provided that such
                                         consent shall not be required for an assignment to a reputable Person whose securities
                                         are publicly traded on a national securities exchange, that has appropriate capabilities
                                         and expertise to fulfill LICENSEE’s obligations hereunder and whose annual revenues
                                         in the twelve (12) month period immediately preceding such assignment are greater than
                                         *****. Any attempt by LICENSEE to assign or transfer this Agreement or the rights or
                                         obligations granted herein in contravention of the foregoing shall render such assignment
                                         and transfer void ab initio. For purposes of this Agreement, an “assignment”
                                         includes any change of control of LICENSEE or assignment by operation of law. Subject
                                         to the foregoing, this Agreement shall be binding upon and inure to the benefit of the
                                         Parties and their successors, respective heirs, and legal representatives.

 

		17.2	Severability. In
                                         the event that any provision (or portion thereof) of this Agreement is determined by
                                         a court or arbitration to be unenforceable as drafted by virtue of the scope, duration,
                                         extent or character of any obligation contained herein, it is the Parties’ intention
                                         that such provision (or portion thereof) shall be construed in a manner designed to effectuate
                                         the purposes of such provision to the maximum extent enforceable under such Applicable
                                         Law. The Parties shall enter into whatever amendment to this Agreement as may be necessary
                                         to effectuate such purposes.

 

		17.3	Agreement by DAVA.
                                         For a period of ***** after the Effective Date, DAVA shall make available to LICENSEE,
                                         at no cost to PFIZER, members of DAVA’s executive, medical, clinical research organization
                                         and information technology teams to provide management support and technical assistance
                                         to LICENSEE in executing the Development Plan and in meeting the Development Milestones.

 

		17.4	Guarantee. For
                                         the period of ***** following the Effective Date, DAVA hereby fully guarantees the due
                                         and prompt performance, compliance, payment and discharge when due of all obligations
                                         (contractual or otherwise) and undertakings of LICENSEE under this Agreement (including
                                         all indemnification obligations and the payment of any and all amounts due or otherwise
                                         payable under this Agreement) in accordance with their terms, and DAVA shall be liable
                                         to PFIZER (and PFIZER can enforce DAVA’s guarantee obligations at any time and
                                         from time to time) to the extent that LICENSEE fails to so comply.

 

		17.5	Governing Law. This
                                         Agreement shall be governed by and construed under the laws in effect in the State of
                                         New York, United States, and, to the extent applicable to patents and Trademarks, unless
                                         otherwise expressly specified, the applicable federal laws of the USA, in each instance
                                         without regard to any conflicts of laws provision thereof or of any other jurisdiction
                                         that would produce a contrary result.

 

    31 

     

    

 

		17.6	Force Majeure. Except
                                         with respect to delays or nonperformance caused by the negligent or intentional act or
                                         omission of a Party, any delay or nonperformance by such Party (other than payment obligations
                                         under this Agreement) will not be considered a breach of this Agreement to the extent
                                         such delay or nonperformance is caused by acts of God, natural disasters, acts of the
                                         government or civil or military authority, fire, floods, epidemics, quarantine, energy
                                         crises, war or riots or other similar cause outside of the reasonable control of such
                                         Party (each, a “Force Majeure Event”); provided that the Party
                                         affected by such Force Majeure Event will promptly begin or resume performance as soon
                                         as reasonably practicable after the event has abated.

 

		17.7	Waivers and Amendments.
                                         The failure of any Party to assert a right hereunder or to insist upon compliance
                                         with any term or condition of this Agreement shall not constitute a waiver of that right
                                         or excuse a similar subsequent failure to perform any such term or condition by the other
                                         Party. No waiver shall be effective unless it has been given in writing and signed by
                                         the Party giving such waiver. No amendment, supplement or modification of this Agreement
                                         shall be binding on the Parties, unless it is in writing and signed by authorized representatives
                                         of each Party.

 

		17.8	Relationship of the
                                         Parties. Nothing contained in this Agreement shall be deemed to constitute a partnership,
                                         joint venture, or legal entity of any type between PFIZER and LICENSEE, or to constitute
                                         one Party as the agent of the other. Moreover, each Party agrees not to construe this
                                         Agreement, or any of the transactions contemplated hereby, as a partnership for any tax
                                         purposes. Each Party shall act solely as an independent contractor, and nothing in this
                                         Agreement shall be construed to give any Party the power or authority to act for, bind
                                         or commit the other Party.

 

		17.9	Notices. All notices,
                                         consents, waivers, and other communications under this Agreement must be in writing and
                                         will be deemed to have been duly given when: (a) delivered by hand (with written confirmation
                                         of receipt); (b) sent by fax (with written confirmation of receipt); provided that
                                         a copy is sent by an internationally recognized overnight delivery service (receipt
                                         requested); or (c) when received by the addressee, if sent by an internationally recognized
                                         overnight delivery service (receipt requested), in each case to the appropriate addresses
                                         and fax numbers set forth below (or to such other addresses and fax numbers as a Party
                                         may designate by written notice):

 

If to PFIZER:

 

PFIZER Inc.

East 42nd Street

New York, NY 10017

Fax: 646-348-8157

Attention: General
Counsel

 

If to LICENSEE:

 

AROG PHARMACEUTICALS,
LLC

Four Forest Plaza,

Merit Drive, Suite
820.

Dallas, TX, 75251 [.]

Fax: 214-360-7470

Attention: Dr. Vinay
Jain

 

    32 

     

    

 

		17.10	Further Assurances.
                                         LICENSEE and PFIZER hereby covenant and agree without the necessity of any further
                                         consideration, to execute, acknowledge and deliver any and all such other documents and
                                         take any such other action as may be reasonably necessary or appropriate to carry out
                                         the intent and purposes of this Agreement.

 

		17.11	No Third Party Beneficiary
                                         Rights. This Agreement is not intended to and shall not be construed to give any
                                         Third Party any interest or rights (including any third party beneficiary rights) with
                                         respect to or in connection with any agreement or provision contained herein or contemplated
                                         hereby.

 

		17.12	Entire Agreement;
                                         Confidentiality Agreement.

 

17.12.1
This Agreement, together with its Schedules, sets forth the entire agreement and understanding of the Parties as to the subject
matter hereof and supersedes all proposals, oral or written, and all other prior communications between the Parties with respect
to such subject matter, including that certain Confidentiality Agreement by and between the Parties, dated October 12, 2009 (“CDA”).
The Parties acknowledge and agree that, as of the Effective Date, all Confidential Information (as defined in the CDA) disclosed
by PFIZER or its Affiliates pursuant to the CDA shall be considered PFIZER’s Confidential Information and subject to the
terms set forth in this Agreement.

 

17.12.2
In the event of any conflict between a material provision of this Agreement and any Schedule hereto, the Agreement shall control.

 

		17.13	Counterparts. This
                                         Agreement may be executed in two or more counterparts, each of which shall be deemed
                                         an original, but all of which together shall constitute one and the same instrument.

 

		17.14	Cumulative Remedies.
                                         No remedy referred to in this Agreement is intended to be exclusive, but each shall
                                         be cumulative and in addition to any other remedy referred to in this Agreement or otherwise
                                         available under law.

 

    33 

     

    

 

		17.15	Waiver of Rule of
                                         Construction. Each Party has had the opportunity to consult with counsel in connection
                                         with the review, drafting and negotiation of this Agreement. Accordingly, any rule of
                                         construction that any ambiguity in this Agreement shall be construed against the drafting
                                         Party shall not apply.

 

[SIGNATURES
APPEAR ON FOLLOWING PAGE]

 

 

 

 

    34 

     

    

 

IN WITNESS
WHEREOF, the Parties and DAVA intending to be bound have caused this Agreement to be executed by their duly authorized representatives
in triplicate as of the Effective Date.

 

	AROG PHARMACEUTICALS LLC	 	PFIZER INC.
	 	 	 
	 	 	 
	By:	/s/ Vinay Jain	 	By:	/s/ Garry Nicholson
	Name:	Vinay Jain	 	Name:	Garry Nicholson
	Title:	CEO	 	Title:	President/GM Oncology

 

 

	With respect to Sections 10.3.4, 10.3.5, 17.3 and 17.4, 

DAVA ONCOLOGY, LP	 
	 	 
	 	 
	By:	/s/ Vinay Jain	 
	Name:	Vinay Jain	 
	Title:	CEO	 

 

 

 

 

Signature
Page 

 

     

     

    

 

SCHEDULE
A: DEVELOPMENT PLAN

 

DEVELOPMENT MILESTONE I:
PRECLINICAL STUDIES

 

LICENSEE shall initiate,
within ***** after the Effective Date, ***** preclinical ***** of a Product in a variety of tumors. This includes *****.

 

DEVELOPMENT MILESTONE II:
CLINICAL STUDIES

 

LICENSEE shall initiate,
within ***** after the Effective Date, ***** clinical ***** of a Product. Such clinical ***** may (at LICENSEE’s discretion)
be for one of the following indications:

 

A. *****

 

B. *****

 

DEVELOPMENT MILESTONE III:
FORMULATION

 

LICENSEE shall initiate,
within ***** after the Effective Date, a modified formulation of the Compound.

 

 

    A-1 

     

    

 

SCHEDULE
B: THE COMPOUND

 

PHYSICAL,
CHEMICAL, & PHARMACEUTICAL PROPERTIES

 

CP-868596:

 

CP-868596 refers to the free
base form. CP-868596-50 refers to the lactate salt of CP-868596 and CP-868596-26 refers to the benzenesulfonate salt CP-868596.

 

Chemical Structure:

 

 

BENZENESULFONATE
SALT

 

	Molecular Weight:	601.72 Daltons (CP-868596-26 benzenesulfonate salt)

    443.55 Daltons (CP-868596 free base)
	 	 
	CAS Name:	4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl) methoxy]

    1 Hbenzimidazol-1-yl]-8-quinolinyl]-, monobenzenesulfonate
	 	 
	Molecular Formula:	C26H29N5O2•C6H6O3S
	 	 

 

    B-1 

     

    

 

CP-673,451:

 

Chemical Structure:

 

 

	Molecular Weight:	417.52 Daltons (free base)

    589.71 Daltons (tosylate salt)
	 	 
	CAS Name:	1-{2-[ 5-(2-Methoxy-ethoxy)-benzoimidazol-1-yl]-quinolin-8-yl}-piperidin-4-ylamine
	 	 
	Molecular Formula:	C24H27N5O2
	 	 

 

    B-2 

     

    
 

SCHEDULE
C: PATENT RIGHTS

 

	Application
    Number	Country	Filing
    Date	Date
    Issued	Status
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****

 

    C-1 

     

    

 

	Application
    Number	Country	Filing
    Date	Date
    Issued	Status
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****

 

    C-2 

     

    

 

	Application
    Number	Country	Filing
    Date	Date
    Issued	Status
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****

 

    C-3 

     

    

 

	Application
    Number	Country	Filing
    Date	Date
    Issued	Status
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	 	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****

 

    C-4 

     

    

 

	Application
    Number	Country	Filing
    Date	Date
    Issued	Status
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****

 

    C-5 

     

    

 

	Application
    Number	Country	Filing
    Date	Date
    Issued	Status
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****

 

    C-6 

     

    

 

	Application
    Number	Country	Filing
    Date	Date
    Issued	Status
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****

 

    C-7 

     

    

 

	Application
    Number	Country	Filing
    Date	Date
    Issued	Status
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****

 

    C-8 

     

    

 

SCHEDULE
D: TRANSFER ACTIVITIES

 

		1.	TRANSITIONAL SERVICES

 

		1.1	Document, Information,
                                         and Material Transfer

 

1.1.1       Documentation
to be transferred: The Parties agree as follows with respect to the Compound: (i) PFIZER will provide electronic copies (in
Microsoft Office format and/or in other non-proprietary format) of relevant Documentation, by a method reasonably acceptable to
LICENSEE. (a) To the extent such Documentation exists as of the Effective Date in an electronic format, including scanned versions
of a hardcopy, PFIZER shall provide to LICENSEE only an electronic copy of such Documentation. For Documentation which does not
exist in an electronic format as of the Effective Date, PFIZER shall provide to LICENSEE a physical copy of the Documentation.
(b) Notwithstanding the foregoing, in no event shall PFIZER be required to provide: (i) data or records that include technology
or products other than the Compound, or (ii) laboratory notebooks, internal team meeting minutes, personal notes of PFIZER’s
or any of its Affiliates’ employees or any of PFIZER’s or its Affiliates’ contractors or subcontractors, or
internal intra-PFIZER or intra-PFIZER Affiliate correspondence.

 

		1.2	Transfer of Specimens/Data
                                         Records

 

1.2.1       GLP
Studies: Within ***** of the Effective Date, PFIZER will identify and produce specimens/data records to the extent directly
pertaining to the Compound that were identified in final reports of GLP studies as having been archived at or by PFIZER (the “Items”).

 

1.2.2       Items
to be Transferred: For Items that are in possession of a Third Party, LICENSEE shall coordinate with such Third Party to transfer
the Items, including transfer of the GMP protocols, receiving documentation, insurance requirements and temperature monitors.
For the Items that are in the possession of PFIZER, PFIZER shall package and ship such Items Ex Works (Incoterms 2000) within
***** following PFIZER’s receipt of notice from LICENSEE to an archival facility of LICENSEE’s choice at LICENSEE
expense and direction. This facility must be identified in the aforementioned notice within three (3) months of the Effective
Date. LICENSEE shall bear all costs and expenses incurred by PFIZER after the Effective Date related to packaging and shipping
of Items pursuant to this Section and Section 1.2.1 of this Schedule.

 

		1.3	Regulatory Filings

 

1.3.1       United
States INDs. Within ***** after written notification from LICENSEE that LICENSEE is able to assume all clinical, regulatory,
and safety obligations, PFIZER shall execute all documents (in a form reasonably acceptable to LICENSEE) required to transfer
the sponsorship of all United States INDs to LICENSEE. LICENSEE shall ensure that it is qualified to assume the obligations described
in the foregoing sentence and shall provide the transfer notification to PFIZER within the ***** after the Effective Date to allow
for sufficient time to accomplish the full IND transfer on or prior to expiration of the ***** period following the Effective
Date.

 

    D-1 

     

    

 

1.3.2       Maintenance
of IND. For the period beginning on the Effective Date and ending on the effective date of the transfer of the applicable
IND(s) (i.e., the date that the LICENSEE serves official confirmation of acceptance of regulatory transfer of responsibility,
which, for clarity, shall be no later than expiration of ***** period after the Effective Date), PFIZER shall continue to maintain
the relevant INDs for the Compound, at LICENSEE’s direction and expense (subject to all Applicable Laws).

 

1.3.3       Electronic
Versions of Documents. Within ***** after the Effective Date, PFIZER will deliver electronic files of the sections of all
open INDs for the Compound and any subsequent updates thereto. For Regulatory Filings other than INDs for the Compound, PFIZER
will deliver electronic versions of these filings within ***** of the Effective Date.

 

1.3.4       Other
Regulatory Filings. Where appropriate, within ***** after written notification from LICENSEE that LICENSEE is able to assume
all clinical, regulatory, and safety obligations, PFIZER shall execute all documents (in a form reasonably acceptable to LICENSEE)
required to transfer the sponsorship of all other Regulatory Filings for the Compound to LICENSEE. LICENSEE shall ensure that
it is qualified to assume the obligations described in the foregoing sentence and shall provide the transfer notification within
the ***** after the Effective Date to allow for sufficient time to accomplish the full IND transfer on or prior to expiration
of the six (6) month period following the Effective Date.

 

1.3.5       Trial
Master Files. PFIZER shall forward Trial Master Files (“TMF’s”) or equivalents thereto, for all completed
clinical studies for the Compound (i.e., studies with signed-off final clinical study reports) to the extent Controlled by PFIZER,
to LICENSEE, as promptly as practicable but in no event no later than ***** after receipt of such written request thereof from
LICENSEE.

 

1.3.6       Interaction
with Regulatory Authorities. For the period beginning on the Effective Date and ending on the effective date of the transfer
of the applicable Regulatory Filing, LICENSEE shall lead all interactions with any Regulatory Authority relating to the Compound
(as between PFIZER and LICENSEE). Notwithstanding the foregoing, for the period beginning after the Effective Date and ending
on the effective date of the transfer of the applicable Regulatory Filing in such country, if LICENSEE so reasonably requests,
PFIZER will participate, by telephone, in interactions with Regulatory Authorities relating to any Compound, at LICENSEE’s
direction and expense; provided that LICENSEE shall provide PFIZER written notice at least ***** prior to any such meetings.

 

    D-2 

     

    

 

		1.4	Safety Reporting

 

1.4.1       Unless
otherwise directed by LICENSEE, PFIZER will submit PFIZER-generated CIOMS/serious adverse event reports for the Compound, to the
relevant Regulatory Authority for the period beginning on the Effective Date and ending on the effective date of the transfer
of the applicable IND to LICENSEE.

 

		1.5	Pharmaceutical Sciences/Manufacturing

 

1.5.1       Document
Transfer and Management. PFIZER will disclose all Documentation, including, summary reports, formulation folders, data related
to the pharmaceutical development of the Compound, to LICENSEE no later than ***** after the Effective Date.

 

1.5.2       Inventory
Transfer and Management. PFIZER will transfer all inventories of non-GMP and GMP active pharmaceutical ingredient for the
Compound Controlled by PFIZER as of the Effective Date as described on Schedule E to LICENSEE within ***** after the Effective
Date, unless subject to a separate written supply agreement. After the Effective Date, except to exercise its rights hereunder,
as permitted under a separate supply agreement or as required for the completion of the transition activities described herein,
PFIZER will not provide any Compound or Product(s), whether active pharmaceutical ingredient or finished drug product, to any
Third Party without the prior consent of LICENSEE. After the Effective Date, PFIZER will not provide any documents, information
or data relating to the Compound to any Third Party for purposes of clinical Development or Commercialization without the prior
consent of LICENSEE.

 

1.5.3       Compensation.
LICENSEE shall reimburse PFIZER for all invoiced costs and expenses incurred after the Effective Date in a manner consistent with
the customary invoice practices of any ongoing or agreed manufacturing or packing effort and all invoiced costs and expenses in
a manner consistent with the customary invoice practices for on-going formulation, materials management and stability.

 

		1.6	Subsequent Requests.
                                         LICENSEE may request other documents, information, records or data on an as-needed
                                         basis during the ***** Transition Period. All such LICENSEE requests will be allocated
                                         against the Transfer Activity total effort hours, specified in Section 3.2 of the Agreement
                                         (attached hereto).

 

		2.	DOCUMENTATION. The
complete list of Documentation is as follows:

 

2.1       Pharmaceutical
Product and Supplies

 

2.1.1       Records
pertaining to synthesis, formulation and manufacture of the Product.

 

    D-3 

     

    

 

2.2       Research
and Development

 

2.2.1       Pre-clinical:
Copies of all protocols, data, results, and reports related to pivotal (e.g., GLP) pre-clinical studies for the Compound:

 

2.2.1.1       animal
efficacy studies;

 

2.2.1.2       animal
safety and toxicity studies;

 

2.2.1.3       studies
and reports prepared in support of IND submission(s);

 

2.2.1.4       For
pre-clinical studies performed prior to the IND preparatory phase, results will be provided in summary documents for studies or
portions of non-GLP studies already completed, where no report was intended to be generated.

 

2.2.1.5       Specimens/data
records that were identified in final reports of GLP toxicology studies as having been archived at or by PFIZER to be delivered
to a qualified archival facility of LICENSEE’s choice at LICENSEE’s expense and direction. This facility must be identified
within three (3) months of the Effective Date.

 

2.2.7       Clinical:
Copies of all protocols and amendments, study reports and results (including tables, figures and data) related to the Compound.

 

2.2.8       Adverse
event reports (e.g., Medwatch or equivalent forms) for any and all clinical trials (either investigator-initiated or PFIZER-sponsored).

 

    D-4 

     

    

 

SCHEDULE
E: INVENTORY

 

***** Inventory

 

Drug Product:

 

		1.	*****

 

		2.	*****

 

API:

 

		1.	*****

 

		2.	*****

 

***** Inventory

 

Non-GMP Materials

 

		1.	*****

 

		2.	*****

 

		3.	*****

 

 

    E-1Exhibit 10.9

 

 

CONFIDENTIAL
TREATMENT REQUESTED UNDER RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

[*****]
INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

 

CONFIDENTIAL

 

 

LICENSE
AGREEMENT

 

This
License Agreement (the “Agreement”) is entered into and made effective
as of January 5, 2015 (“Effective Date”) by and between Arog Pharmaceuticals
Inc., a Delaware corporation having a place of business at 5420 LBJ Freeway, Suite 410, Dallas, Texas 75240
(“Company”) and Videra Pharmaceuticals, LLC, a Delaware
limited liability company having a place of business at 5420 LBJ Freeway, Suite 410, Dallas, Texas 75240 (“Licensee”).
Licensee and Company are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

 

RECITALS

 

Whereas,
Licensee desires to obtain from Company an exclusive license under certain patents, know-how and other intellectual property owned
by or licensed to Company; and

 

Whereas,
Company is willing to grant such rights and licenses under the terms and conditions set forth in this Agreement.

 

Now,
Therefore, the Parties agree as follows:

 

Article
1

Definitions

 

As
used herein, the following terms shall have the following meanings:

 

1.1             
“Affiliate” means, with respect to a particular Party or other entity,
a person, corporation, partnership, or other entity that controls, is controlled by or is under common control with such Party
or other entity. For the purposes of this definition, the word “control” (including, with correlative meaning, the
terms “controlled by” or “under common control with”) means the actual power, either directly or indirectly
through one or more intermediaries, to direct or cause the direction of the management and policies of such entity, whether by
the ownership of fifty percent (50%) or more of the voting stock of such entity, or by contract or otherwise.

 

     

     

    

 

1.2             
“Change of Control” means the consummation of: (a) any merger, consolidation,
business combination or sale of shares of stock other than in a direct issuance of shares of stock by a Party for fair value,
that, if completed, will result in the stockholders of such Party prior to such transaction not having voting control of the surviving
entity immediately after the transaction such that they, acting in concert with one another, could not elect a majority of the
board of directors of the surviving entity; or (b) the sale, transfer, exchange or other disposition of all or substantially all
of a Party’s assets or business relating to this Agreement (whether alone or in connection with a sale, transfer, exchange
or other disposition of other assets or businesses of such Party). Notwithstanding the foregoing, Change of Control shall not
include a financing transaction, either in the form of a private equity financing or public offering.

 

1.3             
“Commercially Reasonable Efforts” means: (a) with respect to development
of a Licensee Product, the efforts and expenditures required (i) for such Licensee Product to remain an Active Candidate and (ii)
to seek Regulatory Approval using such efforts and expenditures comparable to those expended by Licensee (including through the
use of Third Parties) to develop products that are at a similar stage of development or product life cycle as the applicable Licensee
Product and that are owned by Licensee or to which Licensee otherwise has rights; and (b) with respect to commercialization of
a Licensee Product, using such efforts and expenditures comparable to those expended by Licensee (including through the use of
Third Parties) to commercialize products that are at a similar stage of development or product life cycle as the applicable Product
and that are owned by Licensee or to which Licensee otherwise has rights; provided that with respect to (a)(ii) and (b), the efforts
and expenditures by Licensee shall be no less than the greater of (x) the efforts and expenditures commonly expended by an entity
similarly situated to Licensee with respect to products that are at a similar stage of development or product life cycle as the
applicable Licensee Product and that are owned by such Person or to which such Person otherwise has rights and (y) where any rights
and/or obligations hereunder have been sublicensed to a Third Party, the efforts and expenditures commonly expended by such Third
Party with respect to development and/or commercialization (as applicable) of products that are at a similar stage of development
or product life cycle as the applicable Licensee Product and that are owned by such Third Party or to which such Third Party otherwise
has rights.

 

1.4             
“Company Know-How” means all Information that is Controlled by Company
as of the Effective Date or during the Term that is associated with, or necessary or reasonably useful for, the development, manufacture,
or commercialization of Licensee Products in or outside the Licensee Primary Field. Notwithstanding the foregoing, if Company
undergoes a Change of Control, Company Know-How shall exclude (a) any Information acquired or developed prior to the Change of
Control transaction by any entity that becomes a successor to, or an Affiliate of, Company as a result of such Change of Control
transaction or (b) any Information acquired or developed by such an entity after the Change of Control transaction to the extent
in connection with the research, development, manufacturing or commercialization of products that are not claimed in the Company
Patents.

 

1.5             
“Company Patents” means (a) the Patents and Patent applications listed
in Exhibit A under the heading “Company Patents”; (b) all divisionals, continuations, and continuations-in-part (to
the extent the claims thereof are entirely supported by one or more Patents and Patent applications listed on Exhibit A under
the heading “Company Patents” to which it claims priority) that claim priority to the Patents or Patent applications
described in subsection (a); (c) any other subsequent Patent application filings in any country worldwide (to the extent the claims
thereof are entirely supported by one or more Patents and Patent applications listed on Exhibit A under the heading “Company
Patents” to which it claims priority); and (d) all Patents granted with respect to any of the foregoing, and all patents
of addition, restorations, extensions, supplementary protection certificates, registration or confirmation patents, reissues and
re-examinations of any of the foregoing; each of the foregoing (a) through (d), to the extent Controlled by Company.

 

    2 

     

    

 

1.6             
“Company Primary Field” means the treatment, prevention, amelioration,
or diagnosis of cancer.

 

1.7             
“Company Products” means the Lead Company Product and any other product
the manufacture, use, importation, sale or offer for sale of which would, but for the license granted hereunder, infringe a Valid
Claim of a Licensee Patent in the country in which such product is used, offered for sale, sold, manufactured, imported or exported,
but excluding the Lead Licensee Product upon and after the occurrence of the event described in Section ‎2.4.

 

1.8             
“Company Technology” means the Company Patents and the Company Know-How.

 

1.9             
“Confidential Information” of a Party means any and all Information of
such Party that is disclosed to the other Party under this Agreement, whether in oral, written, graphic, or electronic form.

 

1.10           
“Control” means, with respect to any Information, patent, patent application,
or other intellectual property right, that the applicable Party owns or has a license to such Information, patent, patent application,
or intellectual property right and has the ability to grant to the other Party access to and a license (or sublicense, as applicable)
under same without violating the terms of any agreement or other legally enforceable arrangement with a Third Party.

 

1.11           
“Dollar” means a U.S. dollar, and “$” shall be interpreted
accordingly.

 

1.12           
“Information” means information and data of any type and in any tangible
or intangible form, including without limitation inventions, practices, methods, techniques, specifications, operating procedures,
protocols, formulations, software, formulae, knowledge, know-how (including without limitation any manufacturing, regulatory,
or clinical know-how), skill, experience, test data, analytical and quality control data, stability data, results of studies and
patent and other legal information or descriptions.

 

1.13           
“Lead Company Product” means any product containing 1-(2-(5-((3-methyloxetan-3-yl)methoxy)-1H-benzo
[di imidazol- 1-yl)quinolin-8-yl)piperidin-4-amine (or any salts or formulations thereof), including the product that Company
refers to as “Crenolanib.”

 

1.14          
“Lead Licensee Product” means any product containing 1-(2-(5-(2-methoxyethoxy)-1H-benzo[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine
(or any salts or formulations thereof), including the product that Company refers to as “CP-673,451.”

 

    3 

     

    

 

1.15           
“Licensee Know-How” means all Information that is Controlled by Licensee
as of the Effective Date or during the Term that is associated with, or necessary or reasonably useful for, the development, manufacture,
or commercialization of the Lead Company Product in or outside the Company Primary Field. Notwithstanding the foregoing, if Licensee
undergoes a Change of Control, Licensee Know-How shall exclude (a) any Information acquired or developed prior to the Change of
Control transaction by any entity that becomes a successor to, or an Affiliate of, Licensee as a result of such Change of Control
transaction or (b) any Information acquired or developed by such an entity after the Change of Control transaction to the extent
in connection with the research, development, manufacturing or commercialization of products that are not claimed in the Licensee
Patents.

 

1.16           
“Licensee Patents” means (a) the Patents and Patent applications listed
in Exhibit A under the heading “Licensee Patents”; (b) all divisionals, continuations, and continuations-in-part (to
the extent the claims thereof are entirely supported by one or more Patents and Patent applications listed on Exhibit A under
the heading “Licensee Patents” to which it claims priority) that claim priority to the Patents or Patent applications
described in subsection (a); (c) any other subsequent Patent application filings in any country worldwide (to the extent the claims
thereof are entirely supported by one or more Patents and Patent applications listed on Exhibit A under the heading “Licensee
Patents” to which it claims priority); and (d) all Patents granted with respect to any of the foregoing, and all patents
of addition, restorations, extensions, supplementary protection certificates, registration or confirmation patents, reissues and
re-examinations of any of the foregoing; each of the foregoing (a) through (d), to the extent Controlled by Licensee.

 

1.17           
“Licensee Primary Field” means the treatment, prevention, amelioration,
or diagnosis of all diseases.

 

1.18           
“Licensee Products” means the Lead Licensee Product and any other product
the manufacture, use, importation, sale or offer for sale of which would, but for the license granted hereunder, infringe a Valid
Claim of a Company Patent in the country in which such product is used, offered for sale, sold, manufactured, imported or exported,
but excluding the Lead Company Product upon and after the occurrence of the event described in Section ‎2.4.

 

1.19           
“Licensee Technology” means the Company Patents and the Company Know-How.

 

1.20           
“Net Sales” means the gross amount invoiced by, or on behalf of, Licensee,
its Affiliates and their respective sublicensees for sales of a Licensee Product, less the following deductions if and to the
extent they are included in the gross invoiced sales price of the Licensee Product or otherwise directly incurred by Licensee,
its Affiliates and their respective sublicensees with respect to the sale of the Product:

 

(a)              
rebates, quantity and cash discounts, and other usual and customary discounts to customers;

 

(b)             
taxes and duties paid, absorbed or allowed which are directly related to the sale of the Licensee Product;

 

    4 

     

    

 

(c)             
credits, allowances, discounts and rebates to, and chargebacks for spoiled, damaged, out-dated, rejected or returned Licensee
Product;

 

(d)             
actual freight and insurance costs incurred in transporting the Licensee Product to customers;

 

(e)             
discounts or rebates or other payments required by any Applicable Laws, including any governmental special medical assistance
programs; and

 

(f)             
customs duties, surcharges and other governmental charges incurred in connection with the exportation or importation of
the Licensee Product (subsections (a) through (f), collectively, the “Deductions”).

 

Notwithstanding
anything to the contrary herein, sales between or among Licensee, its Affiliates and its and their sublicensees (the “Selling
Parties”) shall be excluded from Net Sales except where such Affiliates or sublicenses are end users, but Net Sales
shall include subsequent sales by the Selling Parties to Third Parties that are not Selling Parties.

 

The following
principles shall apply to calculating Net Sales:

 

(w)             For
the sale of any Licensee Product that is not invoiced, or is delivered before it is invoiced, Net Sales shall be calculated at
the time of shipment or when such Licensee Product is paid for, if paid for before shipment or invoice.

 

(x)               For
the sale or other disposal of any Licensee Product for non-cash consideration, Net Sales shall be calculated as the fair market
price of such Product in the country of sale or disposal. Notwithstanding the foregoing, provision of a Licensee Product to conduct
pre-clinical or clinical research shall not be deemed to be a sale, so long as such Licensee Product is provided at a price that
does not exceed the reasonably estimated cost of production and distribution thereof.

 

(y)              If
a Licensee Product sold in a particular country contains more than one clinically active ingredient (e.g., such clinically active
ingredients are part of the same therapeutic formulation or are sold as a single package), and one or more of such clinically
active ingredients would be a Licensee Product if sold individually (“Licensed API”), and one or more of the
clinically active ingredients would not be a Licensee Product if sold individually (“Other API”), Net Sales
for such combination (a “Combination Product”) will be calculated on a country-by-country basis, as follows:
(a) by multiplying actual Net Sales of such Combination Product in such country by the fraction A/(A+B) where A is the invoice
price in such country of a Licensee Product containing the Licensed API as the sole active ingredient, if sold separately, and
B is the total invoice price in such country of a product containing the Other API as the sole active ingredient, if sold separately;
(b) if the Other API is not sold separately in said country, by multiplying actual Net Sales of such Combination Product in such
country by the fraction A/C where A is the invoice price in such country of a Licensee Product containing the Licensed API as
the sole active ingredient, if sold separately and C is the invoice price in such country of the Combination Product; (c) if neither
a Licensee Product containing the Licensed API as the sole active ingredient(s) nor any product containing the Other API as the
sole active ingredient are sold separately in such country, in the manner calculated in the then currently largest market (by
sales/country) for the Combination Product (other than the country at issue) where reference prices for the Combination Product,
a product containing the Licensed API as the sole active ingredient and/or any product(s) containing the Other API at issue exist
(but where no such prices have been established by, or under the direct influence of, any governmental entity or agency); and
(d) where none of the foregoing clauses (a) through (c) apply, based upon the mutual agreement of the Parties as to the appropriate
allocation between the Licensed API and the Other API (which agreement shall not be unreasonably withheld or delayed by either
Party).

 

    5 

     

    

 

(z)            Net
Sales shall be determined from books and records maintained by Licensee in accordance with GAAP.

 

1.21           
“Patents” means (a) pending patent applications, issued patents, utility
models and designs; (b) reissues, substitutions, confirmations, registrations, validations, re-examinations, additions, continuations,
continued prosecution applications, continuations-in-part, or divisions of or to any of the foregoing; and (c) extensions, renewals
or restorations of any of the foregoing by existing or future extension, renewal or restoration mechanisms, including supplementary
protection certificates or the equivalent thereof.

 

1.22           
“Pfizer” means PFIZER, Inc.

 

1.23           
“Pfizer Agreement” means that certain License Agreement between Pfizer
and Company, dated as of April 28, 2010, as it may be amended from time to time.

 

1.24           
“Regulatory Approval” means all approvals, including pricing and/or reimbursement
approvals if applicable, necessary for the commercial sale of a Licensee Product in a given country or regulatory jurisdiction.

 

1.25          
“Regulatory Authority” means, in a particular country or jurisdiction,
any applicable governmental authority involved in granting Regulatory Approval in such country or jurisdiction.

 

1.26          
“Regulatory Materials” means regulatory applications, submissions, notifications,
communications, correspondence, registrations, Regulatory Approvals and/or other filings made to, received from or otherwise conducted
with a Regulatory Authority in order to develop, manufacture, market, sell or otherwise commercialize a Licensee Product in a
particular country or jurisdiction.

 

1.27           
“Senior Executive” means the Chief Executive Officer of a Party or duly
appointed representative thereof.

 

1.28           
“Termination Know-How” means all Information Controlled by Licensee or
its Affiliates or their respective sublicensees as of the effective date of termination of this Agreement that is necessary or
reasonably useful for, the development, manufacture, or commercialization of Licensee Products.

 

1.29          
“Termination Patent” means any Patent Controlled by Licensee or its Affiliates
or their respective sublicensees as of the effective date of termination of this Agreement that claims the composition of matter,
manufacture or use of one or more Licensee Products or that would otherwise be infringed, absent a license, by the manufacture,
use or sale of any Licensee Product.

 

    6 

     

    

 

1.30           
“Territory” means all countries of the world.

 

1.31           
“Third Party” means any entity other than (a) Company, (b) Licensee or
(c) an Affiliate of either Party.

 

1.32          
“Valid Claim” means either: (a) a claim of an issued and unexpired Patent
that has not been permanently revoked or declared unenforceable or invalid by an unreversed and unappealable or unreversed and
unappealed decision of a court or other appropriate body of competent jurisdiction; or (b) a claim of a pending patent application
that was filed in good faith and has not been revoked, cancelled, withdrawn, abandoned or finally disallowed without the possibility
of appeal or refiling of such application.

 

Article
2

Licenses

 

2.1             
Licenses to Licensee. Subject to the terms and conditions of this Agreement, Company
hereby grants to Licensee the following licenses:

 

(a)             
an exclusive (even as to Company), royalty-bearing, sublicensable (subject to Section ‎2.3) license, under the
Company Patents and the Company Know-How, to research, develop, use, sell, offer for sale, import, make, and have made the Lead
Licensee Product in the Licensee Primary Field in the Territory.

 

(b)            
an exclusive, royalty-bearing, sublicensable (subject to Section 2.3) license, under the Company Patents and the Company
Know-How, to research, develop, use, sell, offer for sale, import, make, and have made Licensee Products in the Territory (other
than Lead Company Product in the Company Primary Field).

 

2.2             
Licenses to Company. Subject to the terms and conditions of this Agreement, Licensee
hereby grants to Company the following licenses:

 

(a)             
an exclusive (even as to Licensee), perpetual, royalty-free, sublicensable (subject to Section 2.3) license, under the
Licensee Patents and the Licensee Know-How, to research, develop, use, sell, offer for sale, import, make, and have made the Lead
Company Product in the Company Primary Field in the Territory.

 

(b)            
a non-exclusive, perpetual, royalty-free, sublicensable (subject to Section 2.3) license, under the Licensee Patents and
the Licensee Know-How, to research, develop, use, sell, offer for sale, import, make, and have made Company Products in the Territory
(other than Lead Company Product in the Company Primary Field).

 

2.3             
Sublicensing. Each Party shall have the right to grant sublicenses, through multiple
tiers, under any or all of the rights licensed to it in Section ‎2.1 or ‎2.2 (as the case may be). Any sublicense
that either Party grants hereunder shall be consistent with the terms and conditions of this Agreement. Each Party shall remain
primarily responsible for all of its sublicensees’ activities and any and all failures by its sublicensees to comply with
the applicable terms of this Agreement. Any sublicenses granted by Licensee shall comply with the terms of the Pfizer Agreement,
including without limitation the specific requirements set forth in Section ‎2.2 of the Pfizer Agreement. In no event
shall Licensee’s granting of any sublicense relieve Licensee of any of its obligations under this Agreement. Licensee shall
provide Company with a true and complete copy of each sublicense and each amendment thereto within thirty (30) days after each
such sublicense or amendment has been executed, and Licensee agrees that Company may provide a copy of such sublicense to Pfizer.

 

    7 

     

    

 

2.4             
Change of Control. Effective solely upon and from the date of effectiveness of a Change
of Control of either Party, the licenses granted herein shall automatically be amended as follows:

 

(a)             
The definition of Licensee Product shall exclude the Lead Company Product.

 

(b)             
The definition of Company Product shall exclude the Lead Licensee Product.

 

(c)              
The license granted in Section ‎2.1(b) shall not include any right to develop or seek Regulatory Approval for
a Company Product in an indication in the Company Primary Field or to commercialize a Company Product approved for use in an indication
in the Company Primary Field.

 

(d)             
The license granted in Section ‎2.2(b) shall not include any right to develop or seek Regulatory Approval .for
a Company Product in an indication in the Licensee Primary Field or to commercialize a Company Product approved for use in an
indication in the Licensee Primary Field.

 

2.5             
No Other Licenses. Neither Party grants to the other Party any rights or licenses
in or to any intellectual property, whether by implication, estoppel, or otherwise, except to the extent expressly provided for
under this Agreement.

 

2.6             
Right of First Negotiation.

 

(a)             
Upon Licensee’s written request (the “Licensee Notice”) at any time during the ROFN Period (as
defined below), and for a period of ***** after Company receives the Licensee Notice (or such longer period as the Parties may
mutually agree), the Parties shall, in good faith, exclusively negotiate the commercially reasonable terms and conditions under
which the non-exclusive license granted in Section ‎2.1(b) would be converted to an exclusive license with respect
to (i) one or more fields or indications (excluding the Company Primary Field) and/or (ii) one or more Licensee Products (excluding
the Lead Company Product). In the event that the Parties fail to execute a definitive agreement (or amendment) relating to such
field(s) or indication(s) and/or product(s) within such period, then License’s rights with respect to such field(s) or indication(s)
and/or products shall continue to be non-exclusive, and Licensee’s negotiation rights with respect to such field(s) or indication(s)
and/or products shall lapse.

 

    8 

     

    

 

(b)             
Upon Company’s written request (the “Company Notice”) at any time during the ROFN Period, and
for a period of ***** after Licensee receives the Company Notice (or such longer period as the Parties may mutually agree), the
Parties shall, in good faith, exclusively negotiate the commercially reasonable terms and conditions under which the non-exclusive
license granted in Section ‎2.2(b) would be converted to an exclusive license with respect to (i) one or more fields
or indications (excluding the Licensee Primary Field) and/or (ii) one or more Licensee Products (excluding the Lead Licensee Product).
In the event that the Parties fail to execute a definitive agreement (or amendment) relating to such field(s) or indication(s)
and/or product(s) within such period, then Company’s rights with respect to such field(s) or indication(s) and/or products
shall continue to be non-exclusive, and Company’s negotiation rights with respect to such field(s) or indication(s) and/or
products shall lapse.

 

(c)              
For purposes of this Section ‎2.6, “ROFN Period” means the period commencing upon the Effective
Date and ending ***** after the effectiveness of a Change of Control of either Party.

 

2.7             
Pfizer Agreement. To the extent that the license granted by Company under Section
‎2.1 constitutes a sublicense under the rights granted to Company in the Pfizer Agreement, such license is subject
to the terms, conditions, and limitations of the Pfizer Agreement.

 

Article
3

Other Obligations of the Parties

 

3.1             
Development and Commercialization of Products. Licensee shall have sole control over,
and responsibility for, the research, development (including but not limited to, pre-clinical and clinical activities and the
preparation and submission of all required regulatory filings), and commercialization of any Licensee Products, and shall bear
all expenses related thereto. For clarity, Company shall have sole control over, and responsibility for, the research, development
(including but not limited to, pre-clinical and clinical activities and the preparation and submission of all required regulatory
filings), and commercialization of any Company Products, and shall bear all expenses related thereto.

 

3.2             
Information and Reporting. Licensee shall provide to Company, every twelve (12) months
during the term of this Agreement, a written report describing in reasonable detail the development and commercialization efforts
undertaken by or on behalf of Licensee, its Affiliates, or its (sub)licensees with respect to Licensee Products during the prior
twelve (12) months and the anticipated development and commercialization efforts with respect to Licensee Products for the upcoming
twelve (12) months. Company may request additional information related to such development and commercialization activities after
receipt of such report, and, subject to the required consent of any applicable Third Party, Licensee shall provide such requested
information. All information disclosed by Licensee under this Section ‎3.2 shall be treated as the Confidential Information
of Licensee under ‎Article 6.

 

    9 

     

    

 

3.3             
Diligence Obligations. Licensee shall use Commercially Reasonable Efforts to (a) develop
and seek Regulatory Approval for Licensee Products in the Territory, including conducting preclinical activities, clinical trial
design and execution and submission of Regulatory Materials in Licensee’s name to secure Regulatory Approval for the Licensee
Products and (b) commercialize Licensee Products in the Territory.

 

3.4             
Technology Transfer.

 

(a)              
Company shall use reasonable efforts to transfer to Licensee the documents and materials (or copies of such documents or
materials, as determined by Company in its sole discretion) listed on Exhibit B no later than ***** after the Effective Date.
After the expiration of the ***** period described above, Company shall use commercially reasonably efforts to provide additional
tangible manifestations of Licensed Know-How requested by Licensee, to the extent then in Company’s possession. In no event
shall Company be obligated to transfer Information to Licensee under this Section ‎3.4(a) that it does not Control
at such time, or violate any law, statute, ordinance or regulation; provided, however, that, to the extent any obligation to any
Third Party prohibits Company from disclosing particular Information, Company shall use commercially reasonable efforts to secure
the right to disclose such Information to Licensee. For the avoidance of doubt, the transfer of any tangible manifestations of
such Licensed Know-How pursuant to this Section ‎3.4(a) shall not alter the ownership or other rights of any Party
or its Affiliates with respect to such Licensed Know-How. Licensee shall reimburse all reasonable out-of-pocket costs and expenses
incurred by Company in connection with any transfer pursuant to this Section ‎3.4(a).

 

(b)              
EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, ANY INFORMATION OR MATERIALS THAT ARE TRANSFERRED PURSUANT TO THIS SECTION
‎3.4 ARE PROVIDED “AS IS” AND WITHOUT ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING WITHOUT
LIMITATION ANY IMPLIED WARRANTY OF COMPLETENESS, COMPLIANCE WITH REGULATORY STANDARDS OR REGULATIONS, MERCHANTABILITY OR OF FITNESS
FOR ANY PARTICULAR PURPOSE OR ANY WARRANTY THAT THE USE OF SUCH INFORMATION OR MATERIALS WILL NOT INFRINGE OR VIOLATE ANY PATENT
OR OTHER PROPRIETARY RIGHTS OF ANY THIRD PARTY.

 

3.5             
Regulatory Matters.

 

(a)              
Licensee shall own all Regulatory Materials and Regulatory Approvals for Licensee Products in the Territory. Licensee shall
be solely responsible for seeking and maintaining Regulatory Approvals of Licensee Products developed by Licensee throughout the
Territory (in such countries as it selects), and for preparing and filing all Regulatory Materials in connection therewith, in
each case at its sole expense. Company shall assist and cooperate with Licensee in connection with the preparation of such Regulatory
Materials, as reasonably requested by Licensee and at Licensee’s expense.

 

(b)              
Company shall own all Regulatory Materials and Regulatory Approvals for Company Products in the Territory. Company shall
be solely responsible for seeking and maintaining Regulatory Approvals of Company Products developed by Company throughout the
Territory (in such countries as it selects), and for preparing and filing all Regulatory Materials in connection therewith, in
each case at its sole expense. Licensee shall assist and cooperate with Company in connection with the preparation of such Regulatory
Materials, as reasonably requested by Company and at Company’s expense.

 

    10 

     

    

 

Article
4

Financial Terms

 

4.1             
Pfizer Milestone Payments. In partial consideration of the sublicense and rights granted
to it by Company under this Agreement, Licensee shall pay to Company the one-time, non-creditable and non-refundable milestone
payments listed below. Licensee and Company agree that the following payments are pass-through payments intended solely to cover
Licensee’s portion of payments owed by Company to Pfizer under the Pfizer Agreement.

 

(a)              
Licensee shall pay to Company a first milestone payment (“Milestone 1”) within ***** after achievement
of the first milestone listed in Section 5.1.2 of the Pfizer Agreement (the “First Pfizer Milestone”), but
only to the extent the First Pfizer Milestone is triggered by a Licensee Product.

 

(b)              
Licensee shall pay to Company a second milestone payment (“Milestone 2”) within ***** after achievement
of the second milestone listed in Section 5.1.2 of the Pfizer Agreement (the “Second Pfizer Milestone”), but
only to the extent the Second Pfizer Milestone is triggered by a Licensee Product.

 

(c)              
Licensee shall pay to Company a third milestone payment (“Milestone 3”) within ***** after achievement
of the third milestone listed in Section 5.1.2 of the Pfizer Agreement (the “Third Pfizer Milestone”), but
only to the extent the Third Pfizer Milestone is triggered by a Licensee Product.

 

Licensee
shall notify Company as soon as practicable (but in any event within *****) upon achievement of the First Pfizer Milestone, the
Second Pfizer Milestone, or the Third Pfizer Milestone by a Licensee Product.

 

4.2             
Royalties.

 

(a)              
Royalty Rates. Licensee shall pay to Company a non-refundable, non-creditable royalty of ***** of Net Sales of Licensee
Products; provided, however, that the royalty rate applicable to Net Sales of a Licensee Product in the United States shall be
***** upon expiration or abandonment of the last Valid Claim filed in the United States that covers such Licensee Product; provided,
further, that a royalty shall only be due hereunder to the extent that Company is obligated to pay a royalty under the Pfizer
Agreement with respect to such Net Sales.

 

(b)              
Royalty Term. Royalties shall be paid under this Section ‎4.24, on a country-by-country and Licensee
Product-by-Licensee Product basis, during the period of time beginning from ***** until the later of: (i) the expiration or abandonment
of the last Valid Claim in any Company Patent in such country that covers the composition of matter of such Licensee Product,
the manufacture of such Licensee Product in such country with respect to such Licensee Product; (ii) the expiration of any Market
Exclusivity covering such Licensee Product in such country; and (iii) the tenth (10th) anniversary of the First Commercial Sale
of such Licensee Product in such country (the “Royalty Term”).

 

    11 

     

    

 

4.3             
Royalty Reports and Payments. All amounts payable to Company pursuant to Section ‎4.4
shall be paid in Dollars within ***** after the end of each calendar quarter with respect to Net Sales in such calendar quarter.
Each payment of royalties due to Company shall be accompanied by a report that includes reasonably detailed information regarding
monthly calculation of all Net Sales of Licensee Product (including all gross invoiced sales and Deductions) and all royalties
payable under Section ‎4.4 for the applicable calendar quarter.

 

4.4             
Third Party Payments.

 

(a)              
Company Obligations. Company will be solely responsible for all amounts owed to Third Parties after the Effective
Date pursuant to agreements between Company and Third Parties with respect to Licensee Products that were entered into prior to
the Effective Date. Notwithstanding the foregoing, the Parties acknowledge and agree that certain payments in this ‎Article
4 are intended to cover Licensee’s share of payments owed by Company to Pfizer under the Pfizer Agreement.

 

(b)              
Licensee Obligations. Licensee will be solely responsible for all amounts owed to Third Parties after the Effective
Date as a result of, or in connection with, the Development, Commercialization or use of Licensee Product by Licensee, its Affiliates
and their respective sublicensees, or their exercise of their right or performance of their obligations under this Agreement.

 

4.5             
Foreign Exchange. If Licensee, its Affiliates or its sublicensees receive payment
from a Third Party in a currency other than United States dollars for which a royalty or fee is owed under this Agreement, then
sales recorded in local currencies shall be converted to Dollars at the average of the daily foreign exchange rates as reported
by Bloomberg (or any other qualified source that the Parties mutually agree upon in writing) for the calendar quarter in which
such payments occurred, or for periods less than a calendar quarter, the average of the daily rates for such period, as reported
by Bloomberg.

 

4.6             
Payment Method; Late Payments. All payments due to Company hereunder shall be made
in Dollars by wire transfer of immediately available funds into an account designated by Company. To the extent permitted under
applicable laws, if Company does not receive payment of any undisputed sum due to it on or before the due date, interest shall
thereafter accrue on the sum due to Company until the date of payment at a rate that is *****. Such interest shall be calculated
on the basis of a year of three hundred sixty (360) days for the actual number of days payment is delinquent.

 

4.7             
Records; Audits. Licensee and its Affiliates and sublicensees will maintain complete
and accurate records in sufficient detail to permit Company to confirm the accuracy of the calculation of royalty payments and
the achievement of sales milestone events. Upon reasonable prior notice, such records shall be available during regular business
hours for a period of ***** from the end of the calendar year to which they pertain for examination, not more often than once
each calendar year, by an independent certified public accountant selected by Company and reasonably acceptable to Licensee, for
the sole purpose of verifying the accuracy of the financial reports furnished by Licensee pursuant to this Agreement. Any such
auditor shall not disclose Licensee’s Confidential Information, except to the extent such disclosure is necessary to verify
the accuracy of the financial reports furnished by Licensee, its Affiliates, or its sublicensees or the amount of payments due
from Licensee to Company under this Agreement. Any amounts shown to be owed but unpaid shall be paid within ***** from the accountant’s
report, plus interest (as set forth in Section ‎4.8) from the original due date. Company shall bear the full cost of
such audit unless such audit discloses an underpayment by Licensee of more than ***** of the amount due for the period being audited,
in which case Licensee shall bear the full cost of such audit.

 

    12 

     

    

 

4.8             
Taxes.

 

(a)              
Taxes on Income. Each Party shall be solely responsible for the payment of all taxes imposed on its share of income
arising directly or indirectly from the efforts of the Parties under this Agreement.

 

(b)              
Tax Cooperation. The Parties agree to cooperate with one another and use reasonable efforts to reduce or eliminate
tax withholding or similar obligations in respect of royalties, milestone payments, and other payments made by Licensee to Company
under this Agreement. To the extent Licensee is required to deduct and withhold taxes on any payment to Company, Licensee shall
pay the amounts of such taxes to the proper governmental authority in a timely manner and promptly transmit to Company an official
tax certificate or other evidence of such withholding sufficient to enable Company to claim such payment of taxes. Company shall
provide Licensee any tax forms that may be reasonably necessary in order for Licensee not to withhold tax or to withhold tax at
a reduced rate under an applicable bilateral income tax treaty. Each Party shall provide the other with reasonable assistance
to enable the recovery, as permitted by applicable Laws, of withholding taxes, value added taxes, or similar obligations resulting
from payments made under this Agreement, such recovery to be for the benefit of the Party bearing such withholding tax or value
added tax.

 

[Continued
on the Following Page]

 

    13 

     

    

 

Article
5

Patents

 

5.1             
Patent Prosecution.

 

(a)              
Subject to Sections ‎5.1(b) and ‎(c), each Party shall be responsible for, at its sole expense, the
prosecution and maintenance of all Patents that it owns.

 

(b)             
Company shall deliver to Licensee copies of all documents materially related to the prosecution or maintenance of any Company
Patents within a reasonable period of time after such documents are prepared by or received by Company, and in any event a reasonable
amount of time before any such document is filed with or submitted to the applicable patent office or agency. Company shall consider
in good faith any and all reasonable comments or suggestions made by Licensee with respect to such prosecution or maintenance.
If, at any time during the term of this Agreement, Company no longer wishes to file, prosecute, or maintain a patent or patent
application in the Company Patents, it shall notify Licensee in writing of such decision. Company shall provide such notice at
least thirty (30) days prior to abandonment or lapse of such patent or patent application, to the extent practicable in light
of the timing of any notice relating to such patent or patent application. Thereafter, Licensee shall have the right, but not
the obligation, to assume the sole and exclusive responsibility, at its discretion, for the filing, prosecution, and/or maintenance
(as the case may be) of such patent or patent application solely at its own expense. To the extent such patent or patent application
is owned by Company, the Company will, upon request of Licensee in writing, transfer ownership of such patent or patent application
to Licensee. Licensee’s rights under this Section ‎5.1(b) shall be subject and subordinated to the rights of
Pfizer to prosecute and/or maintain any Company Patent.

 

(c)             
Licensee shall deliver to Company copies of all documents materially related to the prosecution or maintenance of any Licensee
Patents within a reasonable period of time after such documents are prepared by or received by Licensee, and in any event a reasonable
amount of time before any such document is filed with or submitted to the applicable patent office or agency. Licensee shall consider
in good faith any and all reasonable comments or suggestions made by Company with respect to such prosecution or maintenance.
If, at any time during the term of this Agreement, Licensee no longer wishes to file, prosecute, or maintain a patent or patent
application in the Licensee Patents, it shall notify Company in writing of such decision. Licensee shall provide such notice at
least thirty (30) days prior to abandonment or lapse of such patent or patent application, to the extent practicable in light
of the timing of any notice relating to such patent or patent application. Thereafter, Company shall have the right, but not the
obligation, to assume the sole and exclusive responsibility, at its discretion, for the filing, prosecution, and/or maintenance
(as the case may be) of such patent or patent application solely at its own expense. To the extent such patent or patent application
is owned by Licensee, the Licensee will, upon request of Company in writing, transfer ownership of such patent or patent application
to Company.

 

    14 

     

    

 

5.2             
Infringement by Third Parties.

 

(a)              
Notice. If either Party becomes aware of any actual or threatened infringement of a Company Patent or a Licensee
Patent, such Party shall promptly notify the other Party in writing (the “Notice”) and the Parties shall confer
in good faith regarding the most appropriate action to take with respect to such infringement. Both Parties shall use their reasonable
efforts in cooperating with each other to terminate such infringement without litigation.

 

(b)              
Enforcement of Company Patents. Unless the Parties otherwise agree, Company shall have the first right, but not
the obligation, to take appropriate action against activities allegedly infringing any patent in the Company Patents, in its own
name and under its sole control. If Company does not take any action against any such activities involving any allegedly infringing
product or service in the Licensee Primary Field (a “Licensee Primary Field Infringement”) within one hundred
twenty (120) days after delivery of the Notice, then Licensee may, upon thirty (30) days’ notice to Company, take appropriate
action against such activities in its own name and under its sole control.

 

(c)              
Enforcement of Licensee Patents. Licensee shall have the first right, but not the obligation, to take appropriate
action against activities allegedly infringing any patent in the Licensee Patents, in its own name and under its sole control.
If Licensee does not take any action against any such activities involving any allegedly infringing product or service in the
Company Primary Field (a “Company Primary Field Infringement”) within one hundred twenty (120) days after delivery
of the Notice, then Company may, upon thirty (30) days’ notice to Licensee, take appropriate action against such activities
in its own name and under its sole control.

 

(d)              
Cooperation; Settlement. Regardless of which Party brings the action (the “Initiating Party”),
the other Party (the “Non-Initiating Party”) hereby agrees to cooperate reasonably in any such effort, all
at the Initiating Party’s expense, and the Parties shall reasonably cooperate to address new facts or circumstances that
come to light during the course of any action relating to the Company Patents or Licensee Patents which may affect the need for
one Party or the other to participate in such action. The Non-Initiating Party agrees to be joined as a party plaintiff, at the
Initiating Party’s expense, in any such action if needed for the Initiating Party to bring or continue an infringement action
hereunder. The Non-Initiating Party shall, at its own expense and with its own counsel, have the right to participate in any action
brought by the Initiating Party. Neither Party may settle any action brought under this Section ‎5.2, or take any other
action in the course thereof, that adversely affects the other Party’s interest in the Licensed Patents or Licensed Know-How,
without the written consent of such other Party, such consent not to be unreasonably withheld.

 

(e)              
Costs; Allocation of Recovery. The costs and expenses of conducting any infringement suit brought under this Section
‎5.2 shall be borne solely by the Initiating Party, unless there is a separate written agreement to share costs between
the Parties. Except as otherwise agreed to in writing by the Parties, any recovery realized by a Party as a result of a litigation
or other action taken under this Section ‎5.2 with respect to any actual or threatened infringement of a Company Patent
or Licensee Patent will first be applied to reimburse the Initiating Party for any actual litigation costs and expenses borne
by the Initiating Party and not otherwise reimbursed, and then applied to reimburse the Non-Initiating Party for any actual litigation
costs and expenses borne by the Non-Initiating Party and not otherwise reimbursed. Any amounts remaining after such reimbursement
(a “Net Recovery”) will be retained by the Initiating Party; provided that if Licensee is the Initiating Party,
the Net Recovery shall be included in Net Sales for the calendar year in which the Net Recovery was received or retained, for
purposes of calculating royalties owed to Company hereunder.

 

    15 

     

    

 

(f)              
Enforcement by Pfizer. Licensee’s rights under this Section 5.2 shall be subject and subordinated to the rights
of Pfizer to enforce the Company Patents.

 

Article
6

Confidentiality

 

6.1             
Confidentiality Obligations. Each Party agrees that, for the term of this Agreement
and for five (5) years thereafter, such Party shall, and shall ensure that its officers, directors, employees and agents shall,
keep completely confidential (using at least the same standard of care as it uses to protect proprietary or confidential information
of its own, but in no event less than reasonable care) and not publish or otherwise disclose and not use for any purpose except
as expressly permitted hereunder any Confidential Information furnished to it by the other Party pursuant to this Agreement (including,
without limitation, know-how of the disclosing Party). The foregoing obligations shall not apply to any Information disclosed
by a Party hereunder to the extent that the receiving Party can demonstrate with competent evidence that such Information:

 

(a)              
was already known to the receiving Party or its Affiliate, other than under an obligation of confidentiality, at the time
of disclosure;

 

(b)              
was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving
Party;

 

(c)              
became generally available to the public or otherwise part of the public domain after its disclosure and other than through
any act or omission of the receiving Party in breach of this Agreement;

 

(d)              
was subsequently lawfully disclosed to the receiving Party or its Affiliate by a Third Party other than in contravention
of a confidentiality obligation of such Third Party to the disclosing Party; or

 

(e)              
was independently developed or discovered by employees of the receiving Party or its Affiliates who had no access to the
Confidential Information of the disclosing Party.

 

6.2             
Authorized Disclosure. Notwithstanding the obligations set forth in Section ‎6.1
and Section ‎6.3, a Party may disclose the other Party’s Confidential Information and the terms of this Agreement
to the extent:

 

    16 

     

    

 

(a)              
such disclosure is reasonably necessary (i) for filing or prosecuting Patents as contemplated by this Agreement; (ii) to
comply with the requirements of Regulatory Authorities with respect to obtaining and maintaining Regulatory Approval of a Licensee
Product or Company Product; or (iii) for prosecuting or defending litigation as contemplated by this Agreement;

 

(b)              
such disclosure is reasonably necessary to its employees, agents, consultants, contractors, licensees or sublicensees on
a need-to-know basis for the sole purpose of performing its obligations or exercising its rights under this Agreement; provided
that in each case, the disclosees are bound by written obligations of confidentiality and non-use consistent with those contained
in this Agreement;

 

(c)              
such disclosure is reasonably necessary to any bona fide potential or actual investor, acquiror, merger partner, or other
financial or commercial partner for the sole purpose of evaluating an actual or potential investment, acquisition or other business
relationship; provided that in connection with such disclosure, such Party shall use all reasonable efforts to inform each disclosee
of the confidential nature of such Confidential Information and cause each disclosee to treat such Confidential Information as
confidential; or

 

(d)              
such disclosure is reasonably necessary to comply with applicable Laws, including regulations promulgated by applicable
security exchanges, court order, administrative subpoena or order.

 

In the event
a Party is required to make a disclosure of the other Party’s Confidential Information pursuant to Section ‎6.2(a)
or ‎(d), such Party shall promptly notify the other Party
such required disclosure and shall use reasonable efforts to obtain, or to assist the other Party in obtaining, a protective order
preventing or limiting the required disclosure.

 

6.3             
Publicity; Term of Agreement.

 

(a)              
The Parties agree that the material terms of this Agreement are the Confidential Information of both Parties, subject to
the special authorized disclosure provisions set forth in this Section ‎6.3.

 

(b)              
If either Party desires to make a public announcement concerning the material terms of this Agreement, such Party shall
give reasonable prior advance notice of the proposed text of such announcement to the other Party for its prior review and approval
(except as otherwise provided herein), such approval not to be unreasonably withheld, except that in the case of a press release
or governmental filing required by law, the disclosing Party shall provide the other Party with such advance notice as it reasonably
can and shall not be required to obtain approval therefor. A Party commenting on such a proposed press release shall provide its
comments, if any, within five (5) business days after receiving the press release for review.

 

Neither
Party shall be required to seek the permission of the other Party to repeat any information regarding the terms of this Agreement
that has already been publicly disclosed by such Party, or by the other Party, in accordance with this Section ‎6.34,
provided such information remains accurate as of such time.

 

    17 

     

    

 

(c)              
The Parties acknowledge that either or both Parties may, at some point during the term of this Agreement, be obligated
to file under applicable Laws a copy of this Agreement with the U.S. Securities and Exchange Commission or other governmental
authorities or otherwise to disclose the terms of this Agreement in securities filings as required by applicable Law. Each Party
shall be entitled to make such a required filing, provided that it requests confidential treatment of the commercial terms and
sensitive technical terms hereof and thereof to the extent such confidential treatment is reasonably available to such Party.
At least five (5) business days prior to such disclosure or filing (or such shorter period as may be required to permit timely
filing or disclosure with the SEC or other governmental authority), the Party required to make such a filing of a copy of this
Agreement will provide the other Party with a copy of this Agreement marked to show provisions for which such Party intends to
seek confidential treatment and shall reasonably consider and incorporate the other Party’s comments thereon that are received
during such five (5) business day period, to the extent consistent with applicable Law governing disclosure of material agreements
and material information that must be publicly filed.

 

Article
7

Representations and Warranties

 

7.1             
Representations and Warranties of Licensee. Licensee hereby represents and warrants
to Company that, as of the Effective Date:

 

(a)              
Corporate Power. Licensee is duly organized and validly existing under the laws of State of Delaware and has full
corporate power and authority to enter into this Agreement and to carry out the provisions hereof.

 

(b)              
Due Authorization. Licensee is duly authorized to execute and deliver this Agreement and to perform its obligations
hereunder. The person executing this Agreement on Licensee’s behalf has been duly authorized to do so by all requisite corporate
action.

 

(c)              
Binding Agreement. This Agreement is a legal and valid obligation binding upon Licensee and enforceable in accordance
with its terms. The execution, delivery and performance of this Agreement by Licensee does not conflict with any agreement, instrument
or understanding, oral or written, to which it is a party or by which it may be bound.

 

(d)              
Validity. Licensee is aware of no action, suit or inquiry or investigation instituted by any person or entity that
questions or threatens the validity of this Agreement.

 

7.2             
Representations and Warranties of Company. Company hereby represents and warrants
to Licensee that, as of the Effective Date:

 

(a)              
Corporate Power. Company is duly organized and validly existing under the laws of State of Delaware and has full
corporate power and authority to enter into this Agreement, to grant the licenses granted hereunder, and to carry out the provisions
hereof.

 

    18 

     

    

 

(b)              
Due Authorization. Company is duly authorized to execute and deliver this Agreement and to perform its obligations
hereunder. The person executing this Agreement on Company’s behalf has been duly authorized to do so by all requisite corporate
action.

 

(c)              
Binding Agreement. This Agreement is a legal and valid obligation binding upon Company and enforceable in accordance
with its terms. The execution, delivery and performance of this Agreement by Company does not conflict with any agreement, instrument
or understanding, oral or written, to which it is a party or by which it may be bound.

 

(d)              
Validity. Company is aware of no action, suit or inquiry or investigation instituted by any person or entity that
questions or threatens the validity of this Agreement.

 

7.3             
Disclaimer. EXCEPT AS EXPRESSLY PROVIDED IN THIS ARTICLE ‎8, EACH PARTY
HEREBY DISCLAIMS ANY AND ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE, AND NON-INFRINGEMENT.

 

Article
8

Indemnification

 

8.1             
Indemnification by Company. Unless otherwise provided herein, Company agrees to indemnify,
hold harmless, and defend Licensee, its Affiliates, and their respective officers, directors, contractors, agents and assigns
(the “Licensee Indemnitees”) from and against any and all third party suits, claims, actions, demands, proceedings,
liabilities, damages, costs, expenses and/or losses, including reasonable legal expenses and attorneys’ fees (collectively,
“Claims”), to the extent arising or resulting, directly or indirectly, from any of the following:

 

(a)              
a breach by Company of a representation, warranty, or covenant of this Agreement; or

 

(b)              
the negligence, recklessness or wrongful intentional acts or omissions of Company.

 

Such indemnity
shall not apply to the extent that the Claim was the result of any breach by Licensee of this Agreement or the negligence, recklessness
or wrongful intentional acts or omissions of a Licensee Indemnitee.

 

8.2             
Indemnification by Licensee. Unless otherwise provided herein, Licensee agrees to
indemnify, hold harmless, and defend Company, its Affiliates, and their respective directors, officers, employees, and agents
(the “Company Indemnitees”) and Pfizer, its Affiliates, and their respective officers, directors, contractors,
agents, assigns and licensors (the “Pfizer Indemnitees”) from and against any and all Claims, to the extent
arising or resulting, directly or indirectly, from any of the following:

 

    19 

     

    

 

(a)              
the development, commercialization and/or use of a Licensee Product by Licensee, its Affiliates, or their respective subcontractors
or sublicensees;

 

(b)              
the negligence, recklessness or wrongful intentional acts or omissions of Licensee, its Affiliates, or their respective
subcontractors or sublicensees;

 

(c)              
a breach by Licensee of a representation, warranty, or covenant of this Agreement; or

 

(d)              
a breach by Licensee or any of its sublicensees of the scope of the licenses set forth in Section ‎2.1.

 

Such indemnity
shall not apply to the extent that the Claim was the result of any breach by Company of this Agreement or the negligence, recklessness
or wrongful intentional acts or omissions of a Company Indemnitee or a Pfizer Indemnitee.

 

8.3             
Control of Defense. Any entity entitled to indemnification under this ‎Article
9 shall give written notice to the indemnifying Party of any Claims that may be subject to indemnification, promptly after learning
of such Claim; provided, however, that failure to provide such notice shall not relieve the indemnifying Party of its indemnification
obligation hereunder, except and only to the extent that the indemnifying Party actually is prejudiced as a direct result of such
failure to provide notice. Within a reasonable time after receiving such notice, the indemnifying Party shall assume the defense
of such Claims with counsel reasonably satisfactory to the indemnified Party. The indemnified Party shall cooperate with the indemnifying
Party in such defense. The indemnified Party may, at its option and expense, be represented by counsel of its choice in any action
or proceeding with respect to such Claim. The indemnifying Party shall not be liable for any litigation costs or expenses incurred
by the indemnified Party without the indemnifying Party’s written consent, such consent not to be unreasonably withheld.
The indemnifying Party shall not settle any such Claim if such settlement (a) does not fully and unconditionally release the indemnified
Party from all liability relating thereto or (b) adversely impacts the rights granted to the indemnified Party under this Agreement,
unless the indemnified Party otherwise agrees in writing.

 

8.4             
Insurance. Licensee shall maintain during the Term and until the later of (a) three
(3) years after termination or expiration of this Agreement or (b) the date that all statutes of limitation covering claims or
suits that may be instituted for personal injury based on the sale or use of a Licensee Product have expired, commercial general
liability insurance from a minimum “A-” AM Bests rated insurance company, including contractual liability, personal
injury and product liability or clinical trials, with coverage limits of not less than ***** per claim and ***** in the aggregate.
Licensee has the right to provide the total limits required by any combination of primary and umbrella/excess coverage. The minimum
level of insurance set forth herein shall not be construed to create a limit on Licensee’s liability hereunder. Such policies
shall name Company, Pfizer and their respective Affiliates as additional insured (via CG20101185) and provide a waiver of subrogation
in favor of Company, Pfizer and their respective Affiliates. Such insurance policies shall be primary and non-contributing with
respect to any other similar insurance policies available to Company, Pfizer and their respective Affiliates. Any deductibles
for such insurance shall be assumed by Licensee.

 

    20 

     

    

 

Article
9

Term; Termination.

 

9.1             
Term. The term of this Agreement shall commence upon the Effective Date and, unless
earlier terminated pursuant to this ‎Article 10, shall remain in effect on a Licensee Product-by-Licensee Product and
country-by-country basis, until the expiration of the Royalty Term of such Licensee Product in such country (the “Term”).

 

9.2             
Termination for Breach. Each Party shall have the right to terminate this Agreement
upon written notice to the other Party if such other Party materially breaches its obligations under this Agreement and, after
receiving written notice from the non-breaching Party identifying such material breach in reasonable detail, fails to cure such
material breach within ***** from the date of such notice.

 

9.3             
Termination for Bankruptcy. Each Party shall have the right to terminate this Agreement
in the event of any of the following: (a) the institution of any bankruptcy, receivership, insolvency, reorganization or other
similar proceedings by or against the other Party under any bankruptcy, insolvency, or other similar law now or hereinafter in
effect, including any section or chapter of the United States Bankruptcy Code, as amended or under any similar laws or statutes
of the United States or any state thereof (the “Bankruptcy Code”), where in the case of involuntary proceedings
such proceedings have not been dismissed or discharged within ***** after they are instituted; (b) the insolvency or making of
an assignment for the benefit of creditors or the admittance by the other Party of any involuntary debts as they mature; (c) the
institution of any reorganization, arrangement or other readjustment of debt plan of the other Party not involving the Bankruptcy
Code; (d) appointment of a receiver for all or substantially all of the other Party’s assets; or (e) any corporate action
taken by the board of directors of the other Party in furtherance of any of the foregoing actions.

 

9.4             
Termination for Challenge to Company Technology. Company shall have the right to immediately
terminate this Agreement at any time after the Effective Date in its entirety or on a country-by-country basis in the event Licensee
or any of its Affiliates or its or their sublicensees contests, challenges, supports or assists any Third Party to contest or
challenge, in any patent office, court, regulatory agency or other forum, Company’s or Pfizer’s ownership of, or rights
in, or the validity, enforceability or scope of, any Company Technology (and such shall be considered a material breach of this
Agreement).

 

9.5             
Termination of Pfizer Agreement. In the event that the Pfizer Agreement terminates,
Licensee agrees that Pfizer shall have the right (in its sole discretion) to assume this Agreement (provided that Pfizer shall
not be obligated to fulfill any obligations to Licensee beyond those obligations required of Pfizer if the Pfizer Agreement had
not terminated). If Pfizer does not exercise such right, this Agreement shall automatically terminate.

 

9.6             
Effect of Termination. Upon any termination (but not expiration) of this Agreement:

 

    21 

     

    

 

(a)              
Regulatory Materials; Data. To the extent permitted by Applicable Laws, Licensee shall transfer and assign to Company
all Regulatory Materials, Regulatory Approvals, and related data and Information relating to the Licensee Products and shall treat
the foregoing as “Confidential Information” of Company (and not of Licensee) under ‎Article 6; provided
that Licensee will be allowed to retain any such materials that a Regulatory Authority requires Licensee to retain under Applicable
Laws, and provided further that Licensee shall have the right, and Company hereby grants to Licensee, effective only upon termination
of this Agreement, a co-exclusive license to use any and all data generated by or on behalf of Licensee or its Affiliates or sublicensees
related to the Licensee Products for the development and commercialization of products other than Licensee Products.

 

(b)              
License to Company. Licensee hereby grants to Company, effective upon such termination, an exclusive, royalty-free,
worldwide license (with the right to grant sublicenses through multiple tiers) under the Termination Know-How and Termination
Patents solely to research, develop, make, have made, use, sell, offer for sale, import Licensee Products in the Field.

 

(c)              
Trademarks. Licensee shall assign to Company all right, title and interest in and to any trademarks then being used
by Licensee, its Affiliates, or its sublicensees in connection with the commercialization of Licensee Products (excluding any
such marks that include, in whole or part, any corporate name or logo of Licensee) throughout the Territory, at Licensee’s
expense.

 

(d)              
Sublicensee. Any sublicense granted under the Company Technology shall automatically terminate and be of no further
force or effect.

 

9.7             
Surviving Obligations. Expiration or termination of this Agreement shall not relieve
the Parties of any obligation accruing prior to such expiration or termination. Sections ‎3.4(b), ‎4.7,
‎4.8, and Articles ‎1, ‎6, ‎8, ‎9, ‎10, and ‎11 of
this Agreement shall survive termination or expiration of this Agreement.

 

Article
10

Governing Law; Dispute Resolution.

 

10.1           
Governing Law. This Agreement shall be governed by and construed under the laws in
effect in the State of New York, United States, and, to the extent applicable to patents and Trademarks, unless otherwise expressly
specified, the applicable federal laws of the USA, in each instance without regard to any conflicts of laws provision thereof
or of any other jurisdiction that would produce a contrary result.

 

10.2           
Legal Compliance. The Parties shall review in good faith and cooperate in taking such
actions to ensure compliance of this Agreement with all applicable Laws.

 

10.3           
Disputes. The Parties recognize that disputes as to certain matters may arise from
time-to-time during the term of this Agreement. It is the objective of the Parties to seek to resolve any issues or disputes arising
under this Agreement in an expedient manner and, if at all possible, without resort to litigation, and to that end the Parties
agree to abide by the following procedures set forth in this ‎Article 10 to resolve any such issues or disputes. The
Parties initially shall attempt to settle any such issue or dispute through good faith negotiations in the spirit of mutual cooperation
between business executives with authority to resolve the dispute.

 

    22 

     

    

 

10.4          
Escalation. Prior to taking action as provided in Section ‎10.5 or ‎10.6
of this Agreement, the Parties shall first submit such dispute to the Parties’ respective Senior Executives for resolution.
The Senior Executives to whom any dispute is submitted shall attempt to resolve the dispute through good faith negotiations over
a reasonable period, not to exceed forty-five (45) calendar days, unless the Senior Executives mutually agree in writing to extend
such period of negotiation. Such forty-five (45) calendar day period shall be deemed to commence on the date the dispute was submitted
to the Senior Executives. The Senior Executives shall, if mutually agreed by the Senior Executives, submit the dispute to voluntary
mediation at such place and following such procedures as the Parties shall reasonably agree. All negotiations pursuant to this
Section ‎10.42 shall be confidential, and shall be treated as compromise and settlement negotiations for purposes of
applicable rules of evidence.

 

10.5           
Arbitration. Any dispute that is not resolved by the Parties by negotiation and/or
mediation pursuant to Sections ‎10.1 and/or ‎10.2 above shall, upon the submission of a written request
of either Party to the other Party, be resolved exclusively by binding arbitration before a three-person panel of arbitrators
(the “Panel”), conducted in accordance with the rules of arbitration of the American Arbitration Association
for commercial disputes (the “Rules”), except to the extent that such Rules are inconsistent with this Agreement.
Each Party shall select one independent, neutral arbitrator (a “Party Arbitrator”), and shall notify the other
Party of its selection of such Party Arbitrator within twenty (20) days after receipt by one Party of the other Party’s
written request for binding arbitration. The two (2) Party Arbitrators shall then mutually select a third arbitrator (a “Neutral
Arbitrator”) in accordance with the Rules. The Panel shall resolve the dispute in accordance with this Agreement and
the substantive rules of law (but not the rules of procedure or conflicts of laws) that would be applied by a federal court sitting
in [New York]. The final decision of the Panel shall be the sole and exclusive remedy of the Parties, shall be final and shall
be fully and irrevocably accepted by the Parties. The prevailing Party may enforce such decision against the other Party in any
court having jurisdiction. The arbitration shall take place in Dallas, Texas, and shall be conducted in the English language.
The Parties agree that they shall share equally the cost of the arbitration filing and hearing fees, and the cost of the arbitrators
that constitute the Panel. Each Party shall bear its own attorneys’ and expert fees and all associated costs and expenses.

 

10.6         
Court Actions. Notwithstanding the above, to the full extent allowed by law, either
Party may bring an action in any court of competent jurisdiction for injunctive relief (or any other provisional remedy) to protect
the Parties’ rights or enforce the Parties’ obligations under this Agreement pending final resolution of any claims
related thereto in an arbitration proceeding as provided above. In addition, either Party may bring an action in any court of
competent jurisdiction to resolve disputes pertaining to the validity, construction, scope, enforceability, infringement or other
violations of patents or other proprietary or intellectual property rights. The Parties shall use their reasonable efforts to
conduct all dispute resolution procedures under this Agreement as expeditiously, efficiently and cost-effectively as possible.

 

    23 

     

    

 

Article
11

General Provisions.

 

11.1           
Notices. All notices required or permitted to be given under this Agreement shall
be in writing and shall be deemed to have been given (a) upon personal delivery to the Party to be notified at the address set
forth below, (b) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid,
to the address set forth below, (c) one (1) day after deposit with a nationally recognized overnight courier, specifying next
day delivery to the address set forth below, with written verification of receipt, or (d) upon confirmation of receipt if sent
by facsimile to the number set forth below.

 

To
Company:

 

Arog
Pharmaceuticals Inc.

5420
LBJ Freeway, Suite 410

Dallas,
Texas 75240

Attn:
CEO

Fax:
(469) 533-3966

 

To
Licensee:

 

Videra
Pharmaceuticals, LLC

5420
LBJ Freeway, Suite 410

Dallas,
Texas 75240

Attn:
CEO

Fax:
(214) 889-7070

 

Any Party
may, by written notice to the other, designate a new address or fax number to which notices to the Party giving the notice shall
thereafter be mailed or faxed.

 

11.2           
Force Majeure. No Party shall be liable for any delay or failure of performance to
the extent such delay or failure is caused by circumstances beyond its reasonable control and that by the exercise of due diligence
it is unable to prevent, provided that the Party claiming excuse uses its best efforts to overcome the same.

 

11.3           
Entirety of Agreement. This Agreement sets forth the entire agreement and understanding
of the Parties relating to the subject matter contained herein and merges all prior discussions and agreements between them, and
no Party shall be bound by any representation other than as expressly stated in this Agreement or a written amendment to this
Agreement signed by authorized representatives of each of the Parties.

 

11.4           
Non-Waiver. The failure of a Party in any one or more instances to insist upon strict
performance of any of the terms and conditions of this Agreement shall not be construed as a waiver or relinquishment, to any
extent, of the right to assert or rely upon any such terms or conditions on any future occasion.

 

    24 

     

    

 

11.5           
Independent Contractors. Each Party shall act solely as an independent contractor,
and nothing in this Agreement shall be construed to give either Party the power or authority to act for, bind or commit the other
Party in any way. Nothing herein shall be construed to create the relationship of partnership, principal and agent, or joint venture
between the Parties.

 

11.6           
Severance. If any Article or part thereof of this Agreement is declared invalid by
any court of competent jurisdiction, or any government or other agency having jurisdiction over either Licensee or Company deems
any Article or part thereof to be contrary to any antitrust or competition laws, then such declaration shall not affect the remainder
of the Article or other Articles. To the extent possible the Parties shall revise such invalidated Article or part thereof in
a manner that will render such provision valid without impairing the Parties’ original intent.

 

11.7           
Assignment. Neither Party shall assign or transfer this Agreement or any rights or
obligations hereunder without the prior written consent of the other, except that a Party may make such an assignment or transfer
without the other Party’s consent to its Affiliates or to a Third Party successor to substantially all of the business of
such Party to which this Agreement relates, whether in a merger, sale of stock, sale of assets or other transaction. Any successor
or assignee of rights and/or obligations permitted hereunder shall, in writing to the other Party, expressly assume performance
of such rights and/or obligations. In the event that Licensee assigns this Agreement (whether pursuant to the above provisions
or otherwise), Licensee shall provide prior written notice of such assignment to Company and to Pfizer. Any attempted assignment
or transfer that does not comply with this Section ‎11.7 shall be of no force or effect.

 

11.8           
Bankruptcy. All rights and licenses granted under this Agreement are, and shall otherwise
be deemed to be, for purposes of Section 365(n) of Title 11, U.S. Code (the “Bankruptcy Code”), licenses of
rights to “intellectual property” as defined under Section 101 of the Bankruptcy Code. In the event of commencement
of a bankruptcy proceeding by or against a Party under the United States Bankruptcy Code, the other Party shall be entitled to
a complete duplicate of (or complete access to, as appropriate) any intellectual property licensed to such other Party hereunder,
and all embodiments of such intellectual property, if not already in its possession, shall be promptly delivered to such other
Party.

 

11.9           
Headings. The headings contained in this Agreement have been added for convenience
only and shall not be construed as limiting.

 

11.10         
Limitation of Liability. NO PARTY SHALL BE LIABLE TO ANOTHER FOR INDIRECT, INCIDENTAL,
CONSEQUENTIAL OR SPECIAL DAMAGES, INCLUDING BUT NOT LIMITED TO LOST PROFITS, ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT,
REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTHING IN THIS SECTION IS INTENDED TO LIMIT OR RESTRICT THE DAMAGES
AVAILABLE TO A PARTY FOR THE OTHER PARTY’S BREACH OF ITS OBLIGATIONS UNDER ARTICLE ‎6 OR THE RIGHTS OR OBLIGATIONS
OF EITHER PARTY UNDER ARTICLE ‎8.

 

    25 

     

    

 

11.11         
Third Party Beneficiary. The Parties agree that Pfizer is an express third party beneficiary
of this Agreement and is entitled to enforce the terms of this Agreement.

 

11.12         
Counterparts. This Agreement may be executed in one (1) or more counterparts, including
by facsimile or other electronic transmission, each of which shall be deemed an original, but all of which together shall constitute
one and the same instrument.

 

 

 

    26 

     

    

 

CONFIDENTIAL

 

In
Witness Whereof, the Parties hereto have duly executed this License Agreement.

 

	 	Arog Pharmaceuticals Inc.
	 	 
	 	 
	 	By:	/s/ Vinay Jain, M.D.
	 	 	Name:Vinay Jain, M.D.
	 	 	Title:Chief Executive Officer

 

 

	 	Videra Pharmaceuticals, LLC
	 	 
	 	 
	 	By:	/s/ Vinay Jain, M.D.
	 	 	Name:Vinay Jain, M.D.
	 	 	Title:Manager

 

 

     

     

    
 

EXHIBIT
A

 

		I.	Patents
                                         Sublicensed from Pfizer and Subsequently Maintained by Company pursuant to the Pfizer
                                         Agreement

 

	Application Number	Country	Filing
    Date	Date
    Issued	Status
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****

 

     

     

    

 

	Application Number	Country	Filing
    Date	Date
    Issued	Status
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****

 

    29 

     

    

 

	Application Number	Country	Filing
    Date	Date
    Issued	Status
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****

 

    30 

     

    

 

	Application Number	Country	Filing
    Date	Date
    Issued	Status
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****

 

    31 

     

    

 

	Application Number	Country	Filing
    Date	Date
    Issued	Status
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	 	*****
	*****	*****	*****	 	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****
	*****	*****	*****	*****	*****

 

[Continued
on the Following Page]

 

    32 

     

    
 

		II.	Patents
                                         Filed by Company, Independent of the Pfizer Agreement

 

	Internal Reference Number	Application
    Number	Country	Filing
    Date	Date
    Issued	Status
	*****	*****	*****	*****	 	*****
	*****	*****	*****	*****	 	*****
	*****	*****	*****	*****	 	*****
	*****	*****	*****	*****	 	*****
	*****	*****	*****	*****	 	*****
	*****	*****	*****	*****	 	*****
	*****	*****	*****	*****	 	*****
	*****	*****	*****	*****	 	*****
	*****	*****	*****	*****	 	*****
	*****	*****	*****	*****	 	*****
	*****	*****	*****	*****	 	*****
	*****	*****	*****	*****	 	*****
	*****	*****	*****	*****	 	*****
	*****	*****	*****	*****	 	*****
	*****	*****	*****	*****	 	*****
	*****	*****	*****	*****	 	*****
	*****	*****	*****	*****	 	*****

 

		III.	Licensee
                                         Patents:

 

	Internal Reference Number	Application
    Number	Country	Filing
    Date	Date
    Issued	Status
	*****	*****	*****	*****	 	*****

 

    33 

     

    

 

CONFIDENTIAL

 

Exhibit
B

Know-How to be Transferred

 

I.       Transfer
of Data and Records

 

		1.	All
                                         data and records to the extent pertaining to the development of the Lead Licensee Product
                                         and the Lead Company Product outside of the Company Primary Field, including, but not
                                         limited to:

 

		a)	Records
                                         concerning the protocols, data, results, and reports related to pre-clinical studies
                                         (e.g., in vitro and animal efficacy, safety, and toxicity studies)

 

		b)	Protocols,
                                         amendments, study reports, and results (including tables, figures, and data)

 

		2.	All
                                         documentation, including, summary reports, formulation folders, data related to the pharmaceutical
                                         development of the Lead Licensee Product and the Lead Company Product

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}]]